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Errata 
 
 
Paper I  
In the Introduction section it should read ”Being a strong acid ( pKa1 1.27 and  pKa2 4.28), 
OX was therefore expected to be suitable for SPE with SAX material.” 
 
In Table I, it should read  ”Current procedure, LC-MSMS   3-11     67       ” 
 
In the Result and discussion section, under 3.1 SPE-LC-MSMS method development it 
should read “….sample loss; and the evaporation and chromatographic-separation times 
required…” 
 
In the Result and discussion section, under 3.7 Evaluation of oxalogenesis in fresh samples 
it should read “As can be seen, the mean concentration of OX increases from a value of  6 
to 49 mol/L….” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10
Introduction  
 
 
1. Oxalic acid, hyperoxaluria, hyperoxalaemia and oxalosis  
 
Oxalic acid or oxalate is a small dicarboxylic acid with molecular mass 90.03 g/mol.  
It is a relatively strong acid with pKa1=1.27 and pKa2= 4.28.   
It is the physical property of its calcium salt which is very insoluble at physiological pH that 
is responsible for the life-threatening property of oxalic acid in humans1. 
 
OH
O
HO
O
 
 
 
 
Figure 1. Oxalic acid 
 
The terms hyperoxaluria refers to increased urinary excretion of oxalic acid , 
hyperoxalaemia refers to increased concentration of oxalate in blood, and the term systemic 
oxalosis or simply oxalosis refers to the accumulation of oxalic acid  in tissues2.   
There are several different causes of hyperoxaluria, -aemia and oxalosis, and many of the 
causes are interactive. If the body burden of oxalate increases, hyperoxaluria will be the 
consequence. Hyperoxalaemia occurs when the body’s ability to excrete oxalate through the 
kidneys decreases, and oxalosis can be the consequence of long term or extensive 
hyperoxalaemia.  Hyperoxaluria/aemia increases the risk of precipitation of calcium oxalate 
crystals in the kidneys (renal oxalosis) and consequently the formation of calcium oxalate 
kidney stones. 
Environmental or secondary hyperoxaluria can be caused by increased ingestion and/or 
absorbtion of dietary oxalic acid, intestinal disease or surgery or alterations in intestinal 
flora. Increased endogenous oxalic acid production, e.g. by ethylene glycol poisoning, can 
also result in secondary hyperoxaluria/oxalosis. Finally, decreased clearance of oxalic acid 
from the body due to renal insufficiency can result in hyperoxalaemia and consequently 
oxalosis. 
Hyperoxaluria/oxalosis is only infrequently caused by genetic factors; the primary 
hyperoxalurias. The different topics will be discussed separately. 
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2. Biochemistry and metabolism 
 
Oxalic acid is a metabolic end product that is excreted almost solely in urine.    
In the body, oxalic acid is derived from two sources: the ingestion of oxalic acid or 
ingestion of precursors of oxalic acid, that is, compounds that are metabolized into oxalic 
acid in the body.  In the following oxalic acid from food is referred to as dietary oxalic acid 
and oxalic acid derived from metabolism of oxalic acid precursors as endogenous oxalic 
acid. From an analytical point of view, an additional source of oxalic acid is of major 
interest: The non-enzymatic conversion of ascorbic acid (vitamin C) into oxalic acid, known 
as oxalogenesis can lead to erroneously high oxalic acid quantified in body fluids.  
The different sources of oxalic acid will be discussed separately. 
 
Dietary oxalic acid 
 
There is considerably controversy surrounding the various factors determining the 
concentration of oxalic acid in urine 3. In 1995, Holmes et al estimated that a healthy diet 
rich in whole grain products, vegetables and fruit may contain close to 200mg of oxalate pr 
day, while a less healthy diet, rich in animal protein, refined sugar and fat may contain less 
than 100 mg of oxalic acid, and that 5-15% of the dietary oxalate is absorbed in the intestine 
depending on co-ingestion of calcium, magnesium and fiber, the latter apparently due to 
reduced transit time 4. The contribution of dietary oxalate to oxalate excreted in urine has 
been reported to be as high as 50% 5.  Many different foods contain oxalate. The high 
oxalate content of dark-green leafy vegetables like spinach and rhubarb is generally known. 
Consumption of 200g boiled rhubarb or spinach has been reported to increase urinary 
excretion of oxalate by 300-400% 6. However, despite high in oxalate content, it is 
important to take into account the relatively low amount of consumption of especially 
rhubarb. Other sources of dietary oxalate like black tea and cocoa (chocolate) may contain 
only moderate amounts of oxalate, but the daily consumption in many individuals might be 
comparably higher. The oxalate content of vegetables depends on the plants maturity and 
age, soil quality, and climate, complicating the accurate assessment of the amount of oxalate 
ingested in diets. As an example, using capillary electrophoresis (CE), the oxalate content of 
sweet potato purchased at three different occasions at the same supermarket was found to 
vary from 0.2 to 86.9 mg oxalate/100g7. Difficulties in obtaining reliable data of the oxalate 
content of food is also hampered by the fact that different analytical methods are used in 
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different studies8;9. Food oxalate analysis is challenging due to the wide range of interfering 
substances present in addition to both the potential loss and generation of oxalate during 
assay 9. Foods contain oxalate in both soluble and insoluble forms, and the ratio of the two 
may have influence on the intestinal absorption and bioavailability of oxalate from different 
food sources. Using different extraction conditions for total and soluble oxalate, Honow et 
al 9 developed a quantitative method for oxalate in foods by anion exchange 
chromatography and detection using an enzyme reactor with oxalate oxidase. The oxalate 
content of about 150 foods has been established using their methodology, some of which are 
found in Table 1.   
 
Table 1. oxalate content of some foods 8;9 
 
 
Food 
 oxalate content 
mg/100g 
  
Food 
 oxalate content 
mg/100g 
  Soluble  Total    Soluble  Total 
 
rhubarb 
  
380 
  
570-1900
  
white bread 
  
4.9-8.6 
  
spinach a   33.3-168  100-627  apple  0.3-1.8  0.4-5.8 
potatoes a  8.8-18.9  8.8-35.3  banana  0.1-2.2  0.1-2.2 
tomato  2.5-4.5  3.7-13.7  orange  0.2  1.8 
beans   1.5  13.9  rye bread  0.9   
asparagus a  0.5-1.1  1.8-3.1  black tea  2.5-6.2   
broccoli a  0.5-1.7  0.8-1.9  cocoa 
powder 
   154-980 
carrot a  2.3  4.9  Beer    1.7-1.8 
rice a  0.4  1.8  Coffee  0.5-0.7   
raspberry  2.7-5.9  11.3-25.7  apple juice  0.07-
0.35 
 0.8-0.9 
carambola  81.4-
185.6 
 212.6-
345.7 
 1 bar with 
chocolate 
 7.1  37.9 
strawberry  0.6-1.9  1.5-4.3       
a  Cooked           
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The oxalate content of the foods ingested will be only one of several variables that influence 
the amount of oxalate absorbed. Other factors will include the bioavailability of the ingested 
oxalate, the amounts of oxalate-binding cations, the inherited capacity to absorb oxalate, the 
transit time in the small and large intestines, and the activity of oxalate-degrading bacteria in 
the large intestine 7. 
 
Bioavailability of oxalic acid 
 
The bioavailability of oxalate in foodstuff depends on its interaction with other components 
of food, especially calcium10. Mixing oxalate containing foods with diary products can 
reduce the amount of oxalate available for absorption, presumably because calcium in the 
diary products precipitates oxalate, and calcium oxalate crystals formed might not at all be 
redissolved under normal gastric conditions 3.  
Soluble oxalate has generally been thought to have higher bioavailability than insoluble 
oxalate. However, a study on the bioavailability of oxalate from oca (oxalis tuberosa), a 
vegetable containing oxalate in soluble form only, was found to be in the same range 
(1.44%) as for spinach (2.44%), containing both soluble and insoluble oxalate. A large 
variation in oxalate uptake from oca among individuals was also found. Still, a reduced 
uptake of  
oxalate from oca was found when the vegetable was consumed with sour cream (containing 
calcium) 11.  
Historically, calcium oxalate stone formers have been advised to convert to a vegetarian 
diet, as the urinary excretion of oxalate was suggested to decrease with a low intake of 
animal proteins (containing oxalate-precursors). However, more recent results show that a 
vegetarian diet results in an increase in oxalate excretion 10;12. The higher urinary oxalate 
excretion in vegetarians most likely is due to an increased ingestion of vegetables rich in 
oxalate. 
Recent results from Thomas et al13 on the dietary influence of intestinal oxalate absorption 
and excretion in healthy volunteers confirmed the increase in oxalate excretion found with a 
vegetarian diet. They also tested the effect not only on vegetarian vs mixed diet, but also 
between low and high oxalate vegetarian diet (70 and 300 mg oxalate/day respectively) that 
was equal in calcium and other nutrients and fluids. Surprisingly, no significant correlation 
in oxalate absorption with dietary oxalate was found. However, this unexpected finding was 
recognized to stem from the fact that although the calcium content of the low and high 
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oxalate diets used in the study was the same, the calcium content of the single meals varied 
thus influencing the bioavailability of oxalate from each meal (tortellini with spinach in 
cream sauce used in the high oxalate-diet). These findings support the view that attention 
must be paid to not only having an adequate daily intake of calcium but also on the timing 
of ingestion in relation to the timing of consumption of foods rich in oxalate13. 
Although oxalate excretion is higher following a vegetarian diet, the calcium excretion is 
lower, even when comparing mixed and vegetarian diets with equal amounts of calcium. 
Calcium excretion is affected by animal protein levels (higher excretion following ingestion 
of animal proteins) resulting in an overall reduced risk of supersaturation and stone 
formation in this section of the population 12.  
 
Absorption of oxalate 
 
Traditionally, the absorption of oxalate has been investigated by use of the radioactive 14C2 
oxalic acid in the so called isotopic method, the use of load method or daily excretion 
method as reviewed by Holmes et al4. More recently, Voss et al described a harmless 13C2 
oxalic acid absorption test as alternative to the use of radioactive oxalate14.  
Oxalate absorption can occur along the entire gastrointestinal tract 4. By administrating an 
oxalate load with 13C2 oxalic acid and measuring the concentration of this isotopically 
labeled oxalate in urine in the following eight hours, a maximum peak of absorption was 
found 2-4 hours post load, which is compatible with absorption in the small intestine15. 
However, these studies of Knight et al also suggest that some individuals (stone formers and 
non-stone formers) have an enhanced absorption in the large intestine. The identification of 
the SLC (solute-linked carrier) gene superfamily has further helped in unrevealing the 
mechanism of intestinal oxalate handling. Several structurally similar proteins encoded by 
the SLC26 gene family are anion transporters having measurable affinity for oxalate and are 
expressed in the intestine. The importance of the anion transporters in oxalate homeostasis 
has been demonstrated by the use of a knock-out mouse model. In SLC26c6 (coding for the 
putative anion transporter PAT-1) knockout mice, the ileal oxalate absorption and 
subsequent urinary oxalate excretion was shown to be enhanced 16.  The complex roles and 
mechanisms of intestinal oxalate transport in oxalate homeostasis has recently been 
reviewed by Hatch et al17.  
Several members of the SLC26 family are expressed in the kidney as well18, and their role 
in renal anion transport is briefly discussed under “renal handling of oxalate”. 
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Oxalate degrading bacteria in the gastro intestinal tract 
 
Oxalobacter formigenes (OF) is an anaerobic bacterium that relies exclusively on 
metabolism of oxalate in the colon for energy. Colonization of the gut with OF has been 
associated with a reduction in risk of recurrent stone disease and significantly lower urinary 
oxalate excretion 19 20. In fact, a single oral dose of OF has been shown to reduce oxalate 
excretion in healthy adults administrating an oxalate load 21. A robust colonization with OF 
has a degrading capacity of up to 1g (11.1mmol) of oxalate/day in the human gut 22. Thus, 
using of OF’s complete dependence of oxalate is at least a theoretical potential tool to 
prevent recurrent stone disease and reduce hyperoxaluria.   
OF produces formate and CO2 (carbon dioxide) as an end product of metabolism. The 
membrane of the bacterium contains an oxalate2- formate1- antiporter that mediates the entry 
of oxalate and export of formate. Two enzymes are involved in the metabolism of oxalate 
into CO2 and formate: formyl-CoA transferase (transferring Coenzyme A from formyl-CoA 
to oxalate) and oxalyl-CoA decarboxylase (decarboxylating oxaloyl-CoA to formyl CoA 
plus CO2). CO2 then diffuses out of the cell 23. Using a polymerase chain reaction (PCR)-
based detection assay Sidhu et al 24 determined the presence of OF in the gastrointestinal 
tract of healthy children. A complete absence of OF in newborns and infants up to 6-9 
months was found, but the bacterium appeared when children reach about one year old, 
indicating that colonization starts when children start crawling about. By 3 to 4 years of age, 
all children were colonized with OF, declining to the adult level of 60-70% between 8 and 
12 years 24.  The reason for the loss of OF is not clear, but the therapeutic use of antibiotics 
may play an important role 23. In fact, the prevalence of colonization of OF has been shown 
to be lower in both healthy individuals and recurrent calcium oxalate stone formers who 
have used antibiotics to which OF is sensitive at any time in the past25. Oxalate secretory 
pathways for extra-renal oxalate elimination have been identified, and it has been 
hypothesized that OF can contribute to maintain a transepithelial gradient favouring passive 
oxalate movement from blood to the intestinal lumen 26. 
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Endogenous oxalate 
 
Approximately 10 to 20 mg of oxalate is produced in an adult human every day, and it is 
widely assumed that the main source of endogenously produced oxalate in humans is the 
liver 27. The major precursor of oxalate is sugars and amino acids, and about 40 percent of 
oxalate synthesis appears to be derived from glycine metabolism 2.  
There are still some unresolved issues in the biochemical reactions in human cells that 
culminate in the synthesis of oxalate 27 2 28. However, the biochemical hallmarks and the 
enzyme deficiencies involved in the metabolic diseases covered in this text, the primary 
hyperoxalurias, are well known. Figure 2 shows the major reactions involved in glycolate, 
glyoxylate and oxalate metabolism in the human hepatocyte 2;29.    
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Figure 2. Major biochemical pathways involved in oxalic acid metabolism in the human 
hepatocyte. 
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Most oxalate precursors are metabolized via glycolate and/or glyoxylate. Immediate 
precursors of the highly reactive glyoxylate are glycolate and glycine. Glycolate is oxidized 
into glyoxylate by glycolate oxidase (GO) or L-2-hydroxy acid oxidase A (not shown), 
while the oxidative deamination of glycine to glyoxylate can be catalyzed by D-amino-acid 
oxidase (DAO) or glycine oxidase (not shown).  Detoxification of glyoxylate by 
transamination into glycine is catalyzed by alanine:glyoxylate aminotransferase (AGT) in 
peroxisomes. In cytosol, the deamination into glycine is catalyzed by glutamate:glyoxylate 
aminotransferase (GGT). In human, AGT is liver-specific while GGT activity is widely 
dispersed. In cytosol, glyoxylate can also be reduced to glycolate by lactate dehydrogenase
(LDH) or glyoxylate reductase (GR) which is also widely dispersed. Oxidation of glyoxylate 
into oxalate is catalyzed by GO in peroxisomes and by LDH in cytosol.  
Glycolate is an important precursor of glyoxylate, but the sources of glycolate has not been 
fully identified. Experiments with collagen ingestion suggests that the metabolism of 
hydroxyproline (an amino acid of collagen), principally occurring in mitochondria of 
hepatocytes and renal proximal tubule cells may be of importance30. AGT 2, converting 
glyoxylate to glycine, has no homology with AGT1 and is found in mitochondria of most 
tissues28. It has also been shown that the main route by which carbohydrates such as glucose 
and fructose are converted to oxalate is through hydroxypyruvate31-34. Hydroxypyruvate is 
converted to glycolaldehyde by hydroxypyruvate decarboxylase (HPD), an enzyme that is 
found in various tissues. The glycolaldehyde is then presumeably oxidized by aldehyde 
dehydrogenase (ALDH) into glycolate. In normal circumstances the in vivo relevance of the 
hydroxypyruvate-to-oxalate pathway is uncertain as most of the hydroxypyruvate would be 
expected to be reduced to D-glycerate catalyzed by D-glycerate dehydrogenase (DGDH)2.  
 
Ethylene glycol poisoning 
 
Ethylene glycol is a common constituent of antifreeze and de-icing solutions, and ethylene 
glycol poisoning can result in acute renal failure and death35;35;36. The toxicity of ethylene 
glycol is linked to its metabolism to oxalate, initially via alcohol dehydrogenase (ADH) to 
glycolaldehyde. Glycolaldehyde is rapidly converted to glycolic acid resulting in the severe 
metabolic acidosis often found in ethylene glycol poisoning. Glycolic acid is slowly 
metabolized to oxalate that can precipitate as calcium oxalate in the kidney. 
It is the calcium oxalate that is responsible for the renal toxicity of ethylene glycol. 
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As the conversion of ethylene glycol into it’s toxic metabolites is catalyzed by ADH, the 
treatment of ethylene glycol poisoning targets the inhibition of this enzyme. Historically, 
ethanol has been used as an antidote as ADH has a higher affinity for ethanol than for 
ethylene glycol. Today, drugs like fomepizole that effectively blocks ADH are used for 
treatment of ethylene glycol poisoning.     
 
Vitamin C 
 
The potential effect of Vitamin C (ascorbate) on endogenous oxalate production and urinary 
oxalate levels is uncertain and investigation of endogenous oxalate production is difficult as 
this requires the ingestion of a diet entirely free of oxalate. However, by comparing the 
urinary oxalate excretion in calcium oxalate stone formers and healthy individuals on a 
totally controlled low-oxalate diet, with and without vitamin C supplement, the stone 
formers, but not the controls, were found to have increased endogenous oxalate production 
and secretion suggesting that vitamin C supplementation might be a risk factor for 
individuals that are predisposed to kidney stones 37. A recent study on oxalate excretion 
following intravenous administration of large doses of ascorbic acid (0.2 to 1.5g/kg body 
weight) in subjects with normal renal function revealed that only about 0.2% of the ascorbic 
acid appeared as oxalate in the urine38.  
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3. Renal handling of oxalate 
 
In the nephron, oxalate is freely filterable at the glomerulus. Further processing of oxalate in 
the tubules may involve tubular reabsorption and secretion modifying the ultimate renal 
excretion of oxalate. However, despite a number of studies published on the renal handling 
of oxalate (e.g. 39;40), relatively little is truly known due to technical difficulties in 
performing such studies (Professor Ross P. Holmes, Department of Urology, Wake Forest 
University School of Medicine, Winston-Salem,USA, personal communication).  
 
Tubular reabsorption and secretion 
 
According to Robertson41 oxalate is reabsorbed in the early proximal tubules. Transcellular 
reabsorption of oxalate depends on anion exchangers, and several members of the 
multifunctional anion exchanger family SLC26 are expressed in the kidneys18. In proximal 
tubules the transporter SLC26a1 is responsible for sulfate and oxalate transport.  
Verkoelen et al42 concluded after reviewing published reports that oxalate is also actively 
secreted in the proximal tubule. Also according to Robertson oxalate is secreted in the late 
proximal tubule 41. Oxalate secretion is associated with the SLC26a6 is a Cl-/anion 
exchanger involved in proximal tubular sodium and chloride absorption with exchange for 
oxalate leading to net oxalate excretion 43;44. 
Apart from kidney function determining the filtration of oxalate, the net renal excretion 
depends also on the degree of tubular reabsorption and secretion. These factors may not be 
constant over time. Actually the renal oxalate handling has been reported to vary with the 
amount of oxalate ingested (from reabsorption during fasting and secretion during high 
oxalate intake) indicating that after an oxalate rich meal the kidney could be secreting 
oxalate for an extended period of time15.  
 
Calcium oxalate stone formation 
The first description of calcium oxalate crystals identified in urine dates back to 183945, but 
as early as in 1810 certain renal stones were found to contain calcium oxalate46. It is not 
surprising that salts may form crystals and stones in the renal tubules and urinary tract since 
the glomerular filtrate is up to 100- fold concentrated during the passage of the nephron with 
modest water intake. 
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The physiochemistry of stone formation in general is complex, and for calcium oxalate 
several mathematical models has been developed to describe the process 41. However, it is 
generally agreed that the initiation and growth of a crystal involves a chemical precipitation 
from a solution that has become supersaturated with respect to stone-forming solutes as the 
glomerular filtrate traverses the nephron, and that factors increasing the transit time 
increases the risk of a crystal to become lodged at some point in the nephron 41;47-49. 
Consequently, hyperoxaluria contribute to calcium oxalate stone formation simply by 
increasing the urinary saturation of calcium oxalate.  
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4. Primary hyperoxaluria 
 
Primary hyperoxaluria (PH) includes two rare, well characterized autosomal reccesive 
diseases: primary hyperoxaluria type 1 (PH1) and primary hyperoxaluria type 2 (PH2) 2;29;50.  
In addition, a third type of primary hyperoxaluria has been suggested 51;52.  
The incidence of PH1 is 1:120 000 live births in Europe 53. Less attention has been paid to 
the elucidation of PH2, probably due to its even greater rarity than PH1. PH2 is often 
considered to be a milder disease than PH1 and a ratio of PH1 to PH2 of  20:1 has been 
estimated54. 
PH is characterized by overproduction and accumulation of oxalate in tissues. The first 
identification of PH was published in 192555, but it took another 25 years before PH was 
first described in detail in a report of oxalosis in a child who died of renal failure56. A few 
years later, in 1954, the familial nature of the disease was emphasized with a report of 
oxalosis and hyperoxaluria in identical twins 57.   
The main elimination of oxalate from the body is by urinary excretion, resulting in the 
characteristic increased urinary concentration of oxalate found in PH.  The excess oxalate 
binds to Ca2+ and forms insoluble calcium oxalate that deposits in the kidney and urinary 
tract.  
To expand knowledge of PH by accumulating information regarding a larger number of 
patients, Lieske et al58 at Mayo Clinic College of Medicine, Rochester, Minn., USA have 
developed an international registry for PH that can be found at59:  
http://mayoresearch.mayo.edu/mayo/research/nephrology/registry.cfm 
By April 2009 (latest update available on the website) 203 patients had been registered. 
 
 
PH1 
 
PH1 is caused by deficiency of the liver specific peroxisomal enzyme AGT (see Figure 2). 
Approximately one-third of the PH1 patients have significant levels of AGT catalytic 
activity, but a unique intracellular protein trafficking defect result in AGT being located in 
mitochondria instead of peroxisomes.  
AGT deficiency has a major impact on glyoxylate detoxification, and failure to detoxify 
glyoxylate within the peroxisomes results in either more glyoxylate being oxidized into 
oxalate by GO or more glyoxylate diffusing into the cytosol. Once in the cytosol, glyoxylate 
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can be oxidized to oxalate by LDH, transaminated to glycine by GGT or reduced to 
glycolate by GR or LDH. The resulting excessive hepatic production of oxalate and 
glycolate is the biochemical hallmark of PH1.  
In PH1, more than 90% of the cases present with symptoms referable to the urinary tract, 
and the most common is calcium oxalate stone disease29. 
According to Cochat et al 53, PH1 typically fits five presentations: 
1) an infantile form with early nephrocalcinosis and kidney failure 
2) recurrent urolithiasis and progressive renal failure leading to a diagnosis of PH1 in 
childhood or adolescence 
3) a late onset form, with occasional stone passage in adulthood 
4) diagnosis given by post-transplant recurrence 
5) pre-symptomatic subjects with family history of PH1 (usually siblings) 
 
A number of case reports have been published on patients presenting with recurrent 
urolithiasis or end stage renal failure who later become diagnosed with PH160-62. Case 
reports describing the extremely rare severe infantile form of PH1 presenting as a life 
threatening condition with end stage renal disease (ESRD) and nephrocalcinosis in a 3-
month old baby63 and the late onset form presenting as chronic pain in both hands in a 61 –
year old man64  are  examples on the enormous spread in the ages at which the disease 
become apparent.   
   
PH 2 
 
PH 2 is caused by a deficiency of the cytosolic enzyme DGDH/GR (see Figure 2). The 
conversion of hydroxypyruvate to D-glycerate catalyzed by DGDH is heavily weighted 
towards the reduction reaction. Thus the biochemical consequence of the enzymatic defect 
in PH2 is a buildup of hydroxypyruvate that instead is reduced to L-glycerate by LDH.  
L-glycerate is normally not detectable in urine.  The exact mechanism of excessive oxalate 
synthesis in PH 2 is not known, and several hypotheses have been advanced. Still, the fact 
that DGDH and GR are different catalytic activities of the same enzyme is regarded the 
most plausible explanation of hyperoxaluria found in PH2. The lack of GR activity in PH2 
is thought to prevent the reduction of glyoxylate to glycolate with the subsequent conversion 
of excess glyoxylate to oxalate by LDH65.    
 
 23
Clinical and biochemical diagnosis of PH 
 
In PH, progressive deposition of calcium oxalate often leads to deteriorating kidney function 
and finally ESRD 2;29.The kidneys ability to excrete oxalate then drops, and the plasma 
concentration increases. Supersaturation with respect to calcium oxalate occurs when the 
plasma concentration of oxalate reaches approximately 40 mol/L in adults66 resulting in 
deposition of calcium oxalate in other organs, especially bones. This systemic oxalosis is a 
common finding in PH. There is an average 5-year time interval from symptom onset to 
diagnosis of PH58. The rarity of the disease and insufficient knowledge about inherited 
urolithiasis is thought to be the explanation of this delayed diagnosis of PH53. Stone forming 
activity in PH2 is lower than in PH1 and systemic oxalosis exceptional. However, 
myocardial oxalosis in a PH2 patient has been reported 54. 
The accumulation of calcium oxalate in PH patients starts when the renal function is only 
slightly impaired and the resulting systemic oxalosis is associated with pathology according 
to the tissue concerned, e.g. bone pain when deposition of calcium oxalate is within the 
bone.  
 
Biochemical findings 
 
PH is most commonly diagnosed by measuring oxalate excretion, and the oxalate excretion 
in PH is in general grossly elevated. In addition, increased urinary glycolic acid in PH1 and 
L-glyceric acid in PH2 are normally found. However, in PH1 the increased concentration of 
oxalate in body fluids is not always associated with increased concentration of glycolic acid. 
Differences in relative contributions made by the different enzymes involved in oxidation 
and reduction of glycolic acid (GO, LDH and GR) is a possible explanation for the 
considerable biochemical heterogeneity in PH1 with respect to the ratio of glycolic acid and 
oxalate excreted in urine.  
In PH, when glomerular filtration rate (GFR) falls below 30-50ml/min pr 1.73 m2   systemic 
oxalosis starts to occur 53 (see “Kidney failure and hyperoxalaemia” on page 36 for 
explanation of GFR). The major compartment of the insoluble oxalate pool is bone, and the 
bone content of oxalate has been reported to be much higher in PH1 patients than in patients 
with ESRD due to other causes. 67.   
Concomitant with the decreasing urinary excretion of oxalate following renal insufficiency 
is the increase in plasma oxalate.  
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Thus, the biochemical findings in PH vary during the course of the disease (See  Figure 3). 
With sufficient renal function, a normal or close to normal plasma level of oxalate combined 
with a grossly elevated urinary oxalate excretion are the typical laboratory findings. 
However, significantly increased plasma concentration of oxalate has been reported in 
children with PH despite even with a normal kidney function68. With deteriorating kidney 
function, oxalate excretion can drop to normal values while the plasma concentration 
increases dramatically. As a consequence, analysis of oxalic acid in both plasma and urine 
are important in laboratory diagnosis of PH. 
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Figure 3. Dependence of kidney function on the biochemical findings in PH.  
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Enzymatic diagnosis 
 
Differential diagnosis between the two subtypes of PH is essential if liver transplantation is 
considered, as the defect in PH1 is a liver specific enzyme and in PH2 the deficient enzyme 
is widely dispersed. For definite diagnosis of PH1, measurement of the activity of AGT in 
liver needle biopsies can be performed 2, and by immunoelectron microscopy the subcellular 
distribution can be determined 69. There is no clear relationship between clinical severity 
and residual AGT catalytic activity62. For definitively diagnosis of PH2, measurement of the 
GR activity in a liver biopsy has traditionally been performed although the deficient enzyme 
in PH2, DGDR/GR, is expressed in virtually every tissue in the body. As a result, the 
utilization of more readily available cells for enzymatic diagnosis of PH2 has been 
suggested. A relatively simple assay for spectrophotometric quantification of GR and 
DGDR activity in blood mononuclear cells has been described that could potentially be used 
as a minimally invasive diagnostic test for PH270;71. 
 
Molecular genetics of PH 
 
The deficient enzyme in PH1, AGT,  is encoded by a single gene, AGXT, and the gene 
comprised of 11 exons, spanning approximately 10kb, and maps to chromosome 2q37.372. A 
total of 146 mutations scattered across the gene have been described, with all exons 
represented. Major or minor deletions and insertions account for 25% of the mutations, 
while the majority (75%) is point mutations 73. The first mutation to be described and also 
the most common is a Gly170Arg replacement which is found in about 30% of PH1 mutant 
alleles 74. This common mutation enhances the strength of a functionally weak 
mitochondrial targeting sequence generated by a Pro11Leu polymorphism and together, the 
mutation and the polymorphism are responsible for the peroxisome-to-mitochondria  
mistargeting of AGT75. 
PH2 
The deficient enzyme in PH2, GR/HPR, is encoded by the GRHPR gene with 9 exons, 
spanning 9kb, and maps to chromosome 976. Fifteen mutations spread throughout the nine 
exons have been described 77. 
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Treatment of PH 
 
Following the general order of disease progression, the first strategy in the treatment of PH 
is to reduce the amount of oxalate in the body. Dietary restrictions in intake of oxalate-
containing foods is not regarded as being very efficient in PH62, but reduction of oxalate 
absorption by co-ingestion of calcium can at least theoretically reduce the dietary oxalate 
contribution to the total corporeal oxalate load2. The ability of the bacteria OF to both 
stimulate secretion of endogenous produced oxalate and degrade it in the intestine has been 
proposed as a potential tool for the treatment of PH1 22.  
By orally administrating OF for 4 weeks as frozen paste or enteric-coated capsules 
(delivering OF past the very acidic conditions in the stomach) to a total of 16 PH patients, a 
marked reduction in urinary oxalate or plasma oxalate was observed in the majority of 
patients. In addition, two of the PH patients with systemic oxalosis reported amelioration of 
clinical symptoms during OF therapy 22. The findings of Hoppe et al22 has suggested 
applicability of  OF treatment of PH patients at all stages of the disease, but especially in 
those who are on maintenance dialysis and in renal failure78.   
Many strategies to normalize endogenous oxalate production in PH by reduced intake of 
oxalate precursors or inhibition of the enzymes involved in the production of oxalate (see 
Figure 2) have been proposed, but few has reached general acceptance and use2.  
The role of hydroxyproline derived from meat and gelatin has been given some attention in 
recent years as it has been estimated that up to 20% of the endogenously produced oxalate 
excreted in urine is derived from metabolism of hydroxyproline through the glycolate – 
glyoxylate –oxalate pathway28;30;79.   
Although most attempts at treatment by metabolic intervention and pharmacologic 
manipulation has had limited success, the administration of pyridoxine (vitamin B6) is an 
exception. The effect of pyridoxine in decreasing urinary oxalate excretion in some, but not 
all, PH patients has been known for almost 50 years80. Although attributed to its role as a 
cofactor of AGT, the molecular basis concerning the mechanism of action of pyridoxine still 
remains unknown. The predictability of response has also been largely unknown but recent 
findings indicate that two mutations resulting in peroxisomal-to-mitochondrial mistargeting 
of AGT are associated with pyridoxine response 81. Following these findings, genotyping to 
predict pyridoxine response has been suggested 82.  
If the urine oxalate concentration does not normalize following the strategy mentioned 
above attempting to reduce total body oxalate burden, the second strategy for the treatment 
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of PH is the prevention of calcium oxalate crystallization by hydration or use of 
crystallization inhibitors. If prevention of crystallization fails, the agglomerations may be 
removed by lithotripsy or open surgery, or if renal failure develops the third strategy will be 
dialysis or kidney transplantation2. Clinically the patients present at all stages of the disease, 
thus the order of implementation of treatment strategies in PH varies.  
 
 
 
Organ transplantation in PH1 
 
Early diagnosis and intensified conservative treatment is the main goal in PH, but if 
unsuccessful, several transplantation (TX) strategies are available 83. 
Kidney transplantation alone does not cure the disease, but rather attempts to recover from 
the consequences of lost kidney function and not the basic defect in the liver of PH1 
patients. Following single kidney transplantation, the endogenous oxalate synthesis 
therefore remains elevated. Although in some cases the transplanted kidney can survive for 
a significant length of time, poor prognosis due to recurrence of oxalosis in the graft has 
been well documented and particularly with deceased donor grafts. 61; 84-86.   
Liver transplantation can be regarded as a form of gene therapy as well as enzyme 
replacement therapy as it will supply the missing enzyme in the correct organ (liver), cell 
(hepatocyte) and cell compartment (peroxisome).  However, liver transplantation as a form 
of gene therapy is far from ideal as it involves the replacement of thousands of perfectly 
normal genes just to replace the one that is abnormal. As the function of the liver is normal 
except from the missing AGT activity in PH1 patients, the liver harvested from such a 
patient has been used as a donor organ for a subsequent graft in a second liver recipient in a 
so-called domino procedure. As could be expected, the domino liver recipient rapidly 
developed hyperoxaluria as PH1 in this case was transferred from the donor to the recipient 
87. 
The concept of curing the metabolic defect in PH1 before renal damage occurs by 
performing preemptive liver transplantation has received considerable attention.  Thus, for 
prevention of ESRF and treatment of PH1, preemptive liver transplantation is regarded as a 
powerful tool, however ideal timing and patient selection is regarded difficult as the risk 
associated with surgery and long-term immunosuppression have to be weighed against 
complications related to oxalosis and morbidity88.  
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For PH1 patients with advanced renal insufficiency or ESRD, combined liver/kidney 
transplantation has the advantage of not only correcting the underlying metabolic defect but 
also replacement of renal function 60;85;89.  Combined liver/kidney transplantation can be 
performed concurrent (simultaneous) or sequentially (first liver, then kidney)89.  
The rate of endogenous oxalate synthesis would be expected to drop to normal levels 
immediately after combined liver/kidney transplantation, but it may take months or years to 
normalize the urinary oxalate excretion, depending on the time span of renal insufficiency 
and subsequent oxalate pool size built up prior to transplantation60;85. The accessibility of 
the calcium oxalate stores to the blood stream will influence on the resolubilization rate, and 
thus deposits in slow-turnover bone would be expected to be slowly dissolved. In one 
patient with huge stores of oxalate accumulated in the skeleton prior to transplantation, the 
urinary oxalate excretion was found to drop until month 7 post transplantation but 
reascended in the following months90, probably due to resolubilization of the oxalate stored 
in bones.  
At Oslo University Hospital Rikshospitalet, combined liver/kidney transplantation was 
performed in two PH1 patients in the late 80-ies. They were between 20 and 30 years of age 
at that time. Both patients have been retransplanted with kidneys 4 times. It appears that the 
body load of oxalate is so huge in adult patients that kidney failure occurs in transplants also 
after correction with a liver transplantation. This argues in favor of early liver 
transplantation, especially since the prognosis has improved substantially over the last 
years91  
In Figure 4, the predicted effects of kidney alone and combined kidney/liver transplantation 
on oxalate synthesis, urinary excretion, plasma concentration and total body burden of 
oxalate shown.  
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Figure 4. Effect of kidney alone and combined kidney/liver transplantation on oxalate 
dynamics in PH1. Dotted line represents upper normal level. 
 
 
In PH2, liver transplantation has not been reported.  
This is probably due to the fact that PH2 is regarded as a milder disease than PH1, and in 
addition the liver must contain a significant proportion of the body’s requirement for the 
missing enzyme, GR/DGDH, for liver transplantation to work as an enzyme-replacement 
therapy2. The tissue distribution of GR/DHDG is uncertain, but it has been shown that the 
liver may contain much of the body’s GR activity 92. 
However, isolated kidney transplantation in PH2 has been reported93.  
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5. Secondary hyperoxaluria and/or hyperoxalaemia 
 
As mentioned earlier, secondary hyperoxaluria is due either to excessive dietary oxalate 
intake or increased intestinal oxalate absorption. Secondary hyperoxalaemia is primarily 
associated with decreased renal function. 
 
Hyperoxaluria in recurrent  non-PH calcium oxalate stone formers 
 
The presence of moderate hyperoxaluria in adult recurrent calcium oxalate stone formers is 
controversial. In one study,  supersaturation with regards to calcium oxalate in the urine of 
stone formers and non-stone formers was reported to be not significantly different, but the 
total particle volume in the stone formers were found to be elevated indicating that this 
group have less inhibitory activity of crystal growth94. In other studies, the prevalence of 
hyperoxaluria in calcium oxalate stone formers has been estimated to be in the range of 10-
50%95-97, with no95, or a strong98 correlation between urinary calcium and oxalate.  
In children, the frequency of hyperoxaluria in urolithiasis and/or nephrocalcinosis has been 
reported to be approximately 20% (21 out of 106) 99. Of the 21 children with increased 
urinary oxalate excretion found in the above study, eleven had PH (PH1 in nine and neither 
PH1 or PH2 in two), secondary hyperoxaluria was found in six (two enteric and four 
dietary) and four could not be classified. In the non-PH patients the colonization of OF in 
the gut was tested and found absent in all but one. 
The reason for the discrepancy in the estimation of hyperoxaluria prevalence in stone 
formers is not obvious, but differences in methodologies used for oxalate measurements 
may play a role. In addition, if urinary stones are present at the time of urine collection, the 
urine sample might be depleted of lithogenic substances as the stones continuously increase 
in size by incorporating material from urine100. 
As a result, substantially lower concentrations e.g. of oxalate might be determined resulting 
in false interpretation of urinary risk profile. 
The plasma level of oxalate in paediatric calcium stone formers with normal renal function 
has been reported to be higher (that is, secondary hyperoxalaemia) than in controls, 
especially in those with increased urinary oxalate, indicating that the intestinal oxalate 
absorption might be a significant variable influencing plasma oxalate101. 
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Epidemiology of kidney stones 
 
Epidemiological studies has revealed that the probability of forming kidney stones 
(nephrolithiasis)  differ in various parts of the world being lowest in Asia, medium in 
Europe and highest in Saudi Arabia 102. The chemical composition of urinary stones varies 
with geographical area, sosioeconomic conditions and climate. The incidence of 
nephrolithiasis in western countries has been progressively increasing over the past century, 
which has been attributed to changes in dietary habits and lifestyle 12. The lifetime risk of 
nephrolithiasis is about 10-15% in the developed world and throughout adult life is slightly 
more common in males than in females 49. 
Regarding stone composition, calcium oxalate and/or mixed stones are more frequent in 
young people 103. Overall, calcium oxalate (alone or in combination) accounts for 60-80% of 
all urinary stones and is thus by far the most common constituent 48.  
Interestingly, kidney stones is known to be more frequent in white subjects than in black 
subjects but the underlying mechanisms of the racial difference are not clear102.  Urinary 
calcium has been reported to be lower in black subjects compared to white subjects on 
similar diets 104;105. In addition to the racial difference in urinary calcium, higher pH is found 
in urine from black women compared to white106. By testing the effect of five different 
dietary and supplemental challenges on urinary risk factors for calcium oxalate stones in 
comparable groups of healthy white and black subjects, Lewandowski et al105 found that the 
white subjects were much more sensitive to dietary changes. Based on these findings they 
speculated that Blacks apparent immunity to nephrolithiasis are due to a renal or 
gastrointestinal homeostatic adjustment keeping urinary concentration of lithogenic 
substances in balance105.  
 
Factors affecting calcium oxalate nephrolithiasis 
 
A number of factors affect calcium oxalate nephrolithiasis. The role of diet, colonization 
with OF and the role of calcium will be discussed in the following. 
The role of dietary oxalate in the pathogenesis of calcium oxalate nephrolithiasis is not 
clear15. In a prospective study of more than 240 000 adults, food frequency questionnaires 
were used to asses oxalate intake and the incidence of nephrolithiasis. The mean oxalate 
intakes were found to be 214 mg/d in men, and 185 and 183 mg/d in older and younger 
women, respectively. No significant difference in oxalate intake between stone formers and 
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non-stone formers was observed107, implying that dietary oxalate is not a major risk factor 
for nephrolithiasis. 
In a different study designed to assess the role of dietary oxalate on hyperoxaluria in 
calcium oxalate stone patients, 24-h weighed dietary record and 24-h urine from 93 stone 
formers with, and 93 stone formers without increased urinary oxalate was compared. 
Interestingly, no significant differences in the amount of dietary oxalate or calcium were 
found between the groups suggesting that hyperoxaluria in calcium oxalate stone formers at 
least partly results from intestinal hyperabsorption of oxalate108.  
This hypothesis was further supported by Voss et al14 who compared the absorption of  13C2 
oxalic acid in 120 idiopathic calcium oxalate stone formers and 120 controls. They found 
that the intestinal oxalate absorption was higher in the stone formers than in the healthy 
controls. Oxalate absorption greater than 10% was found in 45.8% of the stone formers in 
comparison to 28.3% in healthy volunteers and they suggested that the harmless 13C2 oxalic 
acid absorption test should be routinely used to identify patients with higher oxalate 
absorption to assist recommendations for individual therapy. Greater oxalate absorption in 
stone formers than non-stone formers was also reported in other studies 14;37, while one 
study found no difference in either intestinal absorption or renal handling of oxalate 
between these groups of individuals 15. 
Regarding the role of calcium, based on studies on normal and stone-forming populations 
there is a general agreement that the mean calcium excretion in stone formers is higher than 
in the normal population5;15. 
The historical underestimated role of oxalate in determining the risk of forming calcium 
oxalate stones has been suggested to result from the difficulties in detecting and measuring 
oxalate reliably in urine. During the same period, the measurement of urinary calcium was 
performed with reasonable accuracy, and thus patients with calcium containing stones were 
assessed by hypercalciuria, and decreased intake of calcium was a dietary advice3. 
However, among others, Holmes et al5 reported a significant decrease in oxalate excretion 
with increased calcium intake. Recently it was shown that gastrointestinal binding of oxalate 
by inclusion of calcium-containing foods in meals was an effective clinical strategy for 
prevention of hyperoxaluria. By increasing the calcium intake in calcium-oxalate stone 
formers, both oxalate excretion and calcium oxalate supersaturation was found to decrease 
while urinary calcium excretion remained unchanged97. The decrease in urinary oxalate with 
increased calcium intake was also found by Matsumoto et al in healthy subjects on liberal 
oxalate intake, but they reported a higher saturation of calcium oxalate following higher 
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calcium intake as the decrease in urinary oxalate did not overcome the effect of increased 
calcium109. They therefore concluded that a high calcium diet and liberal oxalate intake may 
pose an increased risk of calcium oxalate stone formation. It seems reasonable to conclude 
that a combination of mild dietary oxalate restriction in combination with a normal calcium 
intake would give the best protective effect.  
The oxalate to calcium molar ratio in urine is about 1:10, thus an increased intestinal 
absorption of oxalate may lead to hyperoxaluria that significantly enhances the risk of 
formation of urinary stones 13. The reason for the much stronger effect of an increase in 
urinary oxalate compared to an increase in calcium on the supersaturation of urine is 
complicated, but basically it can be explained in the following way: As oxalate (C2O42-) is 
present in a much lower concentration than calcium (Ca2+), an increase in oxalate does not 
significantly reduce the concentration of Ca2+ by complexation, and the product [Ca2+] x 
[C2O42-] rises almost proportionally to the increase in oxalate concentration. In contrast, an 
increase in the concentration of ionized calcium is almost entirely offset by a proportional 
decrease in that of oxalate. As a result, the product of [Ca2+] x [C2O42-] remains almost 
constant in the range of normal to elevated urinary calcium98. 
Regarding the role of colonization with OF, Kaufman et al25 performed a case-control study 
of 247 adult patients with recurrent calcium oxalate stones and 259 matched control subjects 
and found that colonization with OF was associated with a 70% reduced risk of being a 
recurrent calcium oxalate stone former. 
 
 
Enteric hyperoxaluria 
 
Intestinal overabsorption of oxalate with attendant hyperoxaluria has been reported in 
several medical conditions with malabsorption. Under normal circumstances calcium binds 
to most of the intestinal oxalate. Intraluminal free fatty acids can form complexes with 
calcium, but in malabsorption the concentration of intraluminal free fatty acids is increased 
and this completely inhibits the precipitation between dietary oxalate and calcium thus 
leading to more oxalate being available for absorption110.  
 
Intestinal disease or surgery 
 
After bariatric surgery for weight loss a high prevalence of hyperoxaluria in adult patients 
without a history of kidney stones has been reported 111;112. Even non-reversible renal failure 
 34
due to oxalate induced nephropathy has been reported 113.The reason for the observed 
hyperoxaluria in these patients has not been defined, but probably involves malabsorption of 
fatty acids and bile acids resulting in an increased intestinal absorption of oxalate114.  
As mentioned under ”absorption of oxalate”, non-hereditary elevated urinary oxalate but 
also acute renal failure with findings of oxalosis on renal biopsy following bariatric surgery 
has been documented111;112 and suggests that hyperoxaluria may be a common underlying 
risk factor for calcium oxalate nephrolithiasis following this surgical procedure114.  
Children with chronic diarrhoea and short bowel syndrome has been shown to be at risk of 
developing enteric hyperoxaluria due to malabsorption110. Cuvelier et al described a patient 
who received two consecutive renal transplants, both with early graft failure. Biopsies of 
both grafts revealed widespread oxalate deposition suggesting acute oxalate nephropathy. 
The diagnosis of chronic pancreatitis (leading to fat malabsorption) causing enteric 
hyperoxaluria was then made 115. Renal transplantation as a successful treatment of end 
stage renal disease secondary to enteric hyperoxaluria in a patient with Chrohn’s disease has 
also  
been described 116.  
A possible link between the use of the immunosuppressive drug mycophenolate and acute 
renal failure in a recipient of a simultaneous kidney-pancreas transplant has been suggested. 
The patient had prolonged mycophenolate-assosiated diarrhoea and presented with acute 
renal failure caused by oxalosis. By replacing mycophenolate with a different 
immunosuppressant (azathioprine), symptoms greatly improved 117. However, the link 
between mycophenolate and hyperoxaluria has been questioned by others118.  
 It has also been shown that the use of a weight loss drug orlistat (a gastrointestinal lipase 
inhibitor), decreasing dietary fat absorption, increases oxalate absorption and leads to a 
significantly increased urinary oxalate levels that again may increase the risk of stone 
formation. The lipase inhibitor increases the amount of free fatty acids that binds to calcium 
in the intestinal lumen, hereby decreasing the availability of calcium for binding of oxalate. 
As a result the concentration of soluble oxalate increases resulting in increased absorption 
119.  “Orlistat-induced acute oxalate nephropathy” has recently been described 120. 
 
Pancreatic insufficiency 
 
Several cases of alcohol-related chronic pancreatic insufficiency causing diabetes and 
steatorrhea presenting with rapidly progressive renal failure has been published. The high 
 35
rate of deterioration of renal failure in these patients it thought to be a result of the synergy 
between enteric hyperoxaluria and a reduction in renal excretory function caused by early 
diabetic nephropathy121. In a case of late renal transplant dysfunction due to acute oxalate 
nephropathy, a diagnosis of enteric hyperoxaluria secondary to pancreatic insufficiency was 
made. This had occurred because the patient had been non-compliant with his pancreatic 
enzyme replacement therapy. After treatment to reduce the amount of circulating oxalate 
was initiated (haemodialysis, low oxalate and fat diet, appropriate pancreatic enzyme 
replacement therapy), graft function subsequently recovered122.  
 
 
Kidney failure and hyperoxalaemia 
 
Glomerular filtration rate (GFR) describes the flow rate of filtered fluid through the kidney.  
Adjusted for body surface area, typical GFR values in adults are 100-130 ml/min/1.73M2. 
Calculation of GFR can be done by measuring any compound that has a steady level in the 
blood, and that is freely filtered but neither reabsorbed nor secreted by the kidneys. 
Creatinine, a break down product of creatine phosphate in the muscle, is freely filterable but 
actively secreted in only very small amounts. The plasma concentration of creatinine is 
therefore commonly used as an indirect marker of kidney function.It has been found that in 
patients with renal failure unrelated to primary hyperoxaluria, the retention of oxalic acid 
increases rapidly when GFR decreases below about 20 ml/min123. 
When the plasma oxalate is increased formation of calcium oxalate crystals may cause 
tubular injury. As renal the function decline, the urinary excretion of oxalate falls causing a 
further increase in plasma oxalate setting up a vicious circle. 
 
Kidney transplantation and hyperoxalaemia 
 
After renal transplantation in end-stage renal patients, accumulated oxalate will be excreted 
creating an increased risk of tubular precipitation, especially in the presence of allograft 
dysfunction as indicated in several biopsy studies 124-126.  
Controversy exists regarding the degree of oxalosis as a complication of chronic renal 
failure. By studying and comparing the occurrence of renal and myocardial oxalosis at 
autopsy in patients with normal renal function, acute renal failure, chronic renal failure, and 
chronic renal failure supported by haemodialysis or peritoneal dialysis, Salyer et al127 found 
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that the incidence and severity of oxalosis was related to the duration of renal failure. 
Extensive renal and myocardial deposits were frequently found in patients with renal failure 
of long duration, but in those on haemodialysis (but not on peritoneal dialysis) less oxalosis 
was found suggesting that haemodialysis ameliorated the oxalosis to some extent127. 
The effect of haemodialysis on oxalosis was further studied by Fayemi et al128. The 
incidence and organ distribution of oxalosis in a group of 80 patients with chronic renal 
failure maintained on haemodialysis for periods ranging from three weeks to seven years 
was examined.  The most frequently involved organs were the kidneys, thyroid, and 
myocardium, and moderate to severe renal oxalosis was found more frequently in patients 
maintained on haemodialysis for longer periods of time128. In the above study, bone oxalosis 
was not studied, but in a patient maintained on haemodialysis for more than four years 
severe oxalosis of bone was found129. Surprisingly, although there was a history of “renal 
disease” in this patient’s brother, it seems that the possibility of primary hyperoxaluria in 
this patient had not been considered. 
To study the magnitude of oxalosis in bone in cases of ESRF, Marangella et al67compared 
the bony content of oxalate on biopsies of the iliac crest in uremic PH-patients and non-PH 
patients who had been on dialysis treatment for several years. In PH patients, but not in the 
non-PH patients, the amount of oxalate accumulated in bone was significantly related to 
time on dialysis. In the non-PH patients, only slightly increased bone oxalate was found 
compared to controls (0.8, 5.1 and 362 mol oxalate/g bony tissue in controls, non-PH and 
PH patients, respectively). In addition, no relationship was found in either group between 
bony oxalate and pre-dialysis plasma levels. The authors concluded that oxalate deposition 
in bone was not a progressive disorder in non-PH patients with ESRF67, in agreement with 
the earlier findings of Tomson et al130 (see under). In contrast to the above findings, oxalosis 
extensively involving bone in patients with chronic renal failure of long duration has been 
reported 131;132.   
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6. Plasma oxalate concentration and oxalosis 
 
The first study on the association between plasma oxalate concentration and tissue 
deposition in non-PH patients was reported in 1988. Plasma oxalate was measured 
postoperatively in a group of patients undergoing renal transplantation, and in a group of 
patients with chronic renal failure in whom plasma oxalate had been measured before death. 
Mild to grossly elevated plasma oxalate was detected in both groups. Renal deposition of 
oxalate was found in half of the patients and was associated with a plasma oxalate 
concentration of >20 mol/L  
(upper reference limit with the reported methodology: 1,5 mol/L). Although many 
different tissue types were examined (but not bone), no extra-renal deposits were found in 
any of the patients. The authors concluded that non-PH patients with chronic renal failure is 
not at great risk of extra-renal oxalosis 130. In a different study, the same researchers found 
that the elevated plasma oxalate found in ESRF was not an important risk factor for cardiac 
disease or vascular calcification in patients maintained on continuous ambulatory peritoneal 
dialysis133.  Borland et al134 compared serum oxalate in patients with chronic renal failure 
given low-protein diet and treated with chronic haemodialysis, peritoneal dialysis as well as 
in others not yet under dialysis treatment. They found that serum oxalate did not reach 
abnormal levels until a very late stage in chronic renal failure 134. However, they used a 
method for oxalate measurement involving initial alkalization of serum and reported an 
upper reference limit of mol/L which seems erroneously high. 
For the formation of calcium oxalate crystals to occur, a state of supersaturation with respect 
to this salt is necessary. It is therefore reasonable to assume that exceeding the solubility 
limit in plasma represents an actual risk for the deposition of calcium oxalate crystals in 
body tissues. Theoretically, a selective accumulation of calcium and oxalate within a tissue 
is an alternative mechanism of the crystal formation.  By measuring and comparing the 
serum supersaturation with respect to calcium oxalate in adult patients who were either 
uremic or had chronic renal insufficiency not requiring dialysis, and healthy controls, 
Worcester et al66 concluded that supersaturation was common in chronic renal failure. The 
calcium oxalate supersaturation was found to correlate strongly with oxalate concentration, 
and above oxalate levels of about 40 mol/L supersaturation occurred. Further, a regression 
relationship between plasma creatinine (as indicator of the level of renal failure) and plasma 
oxalate in adults was constructed indicating that a plasma creatinine of 9 mg/dL (795 
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mol/L) would almost universally result in supersaturation66. A slightly different result was 
found by Marangella et al135 who calculated the state of saturation with respect to calcium 
oxalate monohydrate before and after dialysis in PH patients and non-PH patients on regular 
dialysis treatment. As expected the plasma oxalate concentrations found were elevated in all 
patients and fell after dialysis, but in contrast to the samples from the PH-patients, samples 
from the non-PH patients were only slightly supersaturated before dialysis. These finding 
indicated that dialysis treatment may maintain body fluids below the risk of calcium oxalate 
crystallization, unless the underlying disease is PH. In agreement with Worcester et al, the 
major determinant of the state of saturation with respect to calcium oxalate was found to be 
the plasma oxalate concentration 135. The discrepancy between the level of supersaturation 
reported in the two studies may at least partly be due to differences in analytical methods 
used and consequently normal range reported for oxalate in plasma, mean normal 
concentration 3,8 mol/L in 135  and 10 mol/L in 66.  
In children with chronic renal failure not due to PH, systemic oxalosis is not a common 
finding, but supersaturation with respect to calcium oxalate has been observed when the 
renal function is only moderately reduced, and occurs when the plasma oxalate levels 
reaches about 30 mol/L (Ion chromatography, mean normal concentration 6,43mol/L) 68. 
Even in children with ESRD, systemic oxalosis is not a common finding unless the 
underlying disease is PH. The plasma concentration of crystal inhibitors like citrate and 
sulphate in children has been reported not to differ between PH and non-PH ESRD-patients 
but the plasma oxalate concentration is considerably higher in PH suggesting that plasma 
oxalate measurement alone is sufficient for determining the risk of systemic oxalosis136. The 
reason why plasma calcium oxalate supersaturation does not result in development of 
oxalosis in non-PH patients with ESRD is not fully understood, but may be due to a 
combination of the observed return to calcium oxalate undersaturation after dialysis in non-
PH patients but not in PH patients and perhaps the presence of unknown, protective factors 
that prevent the risk of systemic oxalosis in non-PH children with ESRD136.   
The discrepancy between the findings in different studies on renal failure and oxalosis may 
be partly due to the fact that other factors than the plasma saturation of calciumoxalate may 
play an important role in oxalosis. It has been showed that the occurrence of prior tissue 
damage could represent a crucial predisposing factor in the deposition of calcium oxalate 
crystals137. In rats with chronic renal failure, the effect of increased plasma oxalate, elevated 
plasma ionized calcium and local myocardial tissue damage on myocardial deposition of 
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calcium oxalate was investigated. Interestingly, neither increased plasma levels of calcium, 
oxalate, or both, induced myocardial calcium oxalate crystal deposition (but massive renal 
deposition was found). But, after heterotropic cardiac transplantation (by transplanting into 
the abdomen a heart allograft), elevated oxalate resulted in significant oxalosis in the heart 
allograft, but not in their own heart, indicating that the lack of integrity of local tissue may 
play an important role in oxalosis137.   
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7. Renal transplantation in Norway 
 
Oslo University Hospital Rikshospitalet is the only transplant centre in Norway. It is by far 
the biggest kidney transplant centre in Europe and the number of kidney transplants 
performed approaches 300 during a year. For patients with ESRF, renal replacement therapy 
(RRT) by haemodialysis, peritoneal dialysis or kidney transplantation is active treatment 
options. Transplantation has in general been considered the treatment of choice, after the 
introduction of the kidney transplant program in Norway in 1969. Best results have been 
obtained with a living related donor. The acceptance criteria for transplantation have been 
generous, and in principle transplantation is offered to all patients considered to profit from 
it.  No strict upper or lower age limit has been applied. The results from transplantation of 
patients beyond 70 years have been surprisingly good during the last decade 138. Pre-emptive 
transplantation, that is, transplantation performed before the initiation of chronic 
maintenance dialysis, has always been preferred since the start of an organized 
transplantation programme in Norway 139. For data presented in this thesis, patients were 
recruited during the years 2004 and 2005. Some key numbers related to renal replacement 
therapy and kidney transplantation in Norway for the years 2004, 2005, and 2008140-142 are 
summarized in Table 2. 
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 Table 2. Key numbers in renal replacement therapy (RRT) and renal transplantation in 
Norway, 2004, 2005, and 2008. 
 
Variables Year 
 2004 2005  2008 
Patients receiving RRT 3498 3383  4225 
%  males/females  63.9/36.1 64.5/35.5  67.7/32.3 
New patients entering RRT 459 459  533 
Patients starting dialysis who were 
previously unknown to the renal unit  
 
23 % 
 
29% 
  
30% 
Death in RRT (% of total in RRT) 254 (7.3) 314 (8.4)  330 (7.8) 
Renal transplants at  
OUH Rikshospitalet 
 
265 
 
229 
  
278 
First/second/third/fourth grafts 229/29/7 191/33/4/1  224/48/6 
Graft from living donor   (%) 95 (35.8) 87 (38)  98 (35) 
Pre-emtive transplantation 29 % 33%  43% 
Age range, first graft recipients.  
Years (mean) 
 
2-73 (41.7) 
 
2-75 (44.7) 
  
6-74 (46.7) 
Graft from diseased donor 170 142  180 
Pre-emtive transplantation 18 % 16%  22% 
Age range, first graft recipients. 
years (mean) 
 
1.5-78 (55.8) 
 
8-80 (56.5) 
  
22-82(55) 
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8. Determination of oxalic acid in biological samples 
 
Reliable determination of oxalic acid in biological matrices has over the years proven to be 
very difficult, as evident from the very large number of methods which have been published 
on this topic only to be discarded and replaced by others. 
Methods based on a wide range of analytical principles have been used, and in the 1980’ties 
and 90’ties several review articles on the different methods available up until then was 
published 143-147.  
Some methods have been based on detection of the native compound (oxalic acid itself), 
some on determination of the products of a chemical reaction between oxalic acid and other 
compounds (e.g. H2O2 formed by enzymatic conversion of oxalic acid), and some on 
detection of chemically modified oxalic acid (e.g. di-esters formed by derivatization). 
For most of the methods, some sort of sample preparation was needed to remove interfering 
compounds. For urine, this has generally been achieved by precipitation of oxalate as its 
calcium salt, by liquid-liquid or solid phase extraction, ion chromatography or adsorption 
chromatography. For plasma, removal of proteins is a common initial step of the sample 
preparation procedure either by ultrafiltration or precipitation by acid/heat. The resulting 
deproteinized plasma could then undergo the same procedure as urine. The concentration of 
oxalic acid in plasma is considerably lower than in urine and in addition the sample matrix 
is more complex and thus more extensive sample preparation procedures are often required. 
A phenomenon known as in-vitro oxalogenesis also contributes to the difficulty in obtaining 
reliable measurement of oxalic acid, especially in plasma. As a result the number of 
methods published on determination of oxalic acid in plasma is considerably lower 
compared to methods for urine analysis.  
 
8.1. In-vitro oxalogenesis 
 
In-vitro oxalogenesis, or simply oxalogenesis, is a process in which compounds present in 
the sample is converted to oxalic acid after sample collection and/or during assay. The result 
of oxalogenesis is erroneously elevated oxalic acid measured. As early as in 1933 it was 
reported that ascorbic acid could be oxidized to oxalic acid 148, but this fact was in the 
following decades apparently forgotten by the analytical chemists developing methods for 
oxalic acid determination. The instability of oxalic acid in biological fluids was observed, 
but the identity of the precursor(s) of oxalic acid responsible for oxalogenesis was for a long 
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time not known. However, it was known that glycolic acid could be oxidized to oxalic acid 
and in 1980 Akcay et al published data suggesting that glycolic acid was the source of 
oxalogenesis. 
Several researchers tried, but failed to reproduce these findings 149;150. The fact that ascorbic 
acid (vitamin C) could be oxidized into oxalic acid was rediscovered in the mid 1980’ties151, 
and since then it has been generally accepted that ascorbic acid is the main source of in vitro 
oxalogenesis152;153. The breakdown of ascorbic acid into oxalic acid (and threonic acid) goes 
through several steps in which the last is highly pH dependent and only taking place at 
alkaline pH. A number of different sample preparation procedures including removal of 
ascorbic acid or acidification of sample have been suggested and adapted to prevent 
oxalogenesis.  
 
An overview of the different sample preparation procedures and analytical systems reported 
up to date for oxalic acid determination in plasma and urine follows.  
 
8.2. Sample preparation 
 
The sample preparation procedures used in methods for oxalic acid determination differs 
widely depending on the proceeding analysis technique (e.g. chemical analysis or gas 
chromatography). Therefore, details on the sample preparation procedures adapted are in the 
following given together with the analytical procedure described.   
However, a brief description on the three most commonly used sample preparation 
principles for oxalic acid determination, calcium oxalate precipitation, liquid-liquid 
extraction and solid-phase extraction, will first be presented.  
 
Calcium oxalate precipitation 
 
The precipitation of oxalic acid at alkaline pH as its calcium salt was by far the most 
commonly used cleanup process for the earlier methods of oxalic acid determination. The 
solubility of calcium oxalate is strongly pH dependent being practically insoluble at alkaline 
and neutral pH but soluble at low pH. The main drawback of calcium oxalate precipitation is 
the very long time needed for quantitative precipitation, the co-precipitation of other salts 
such as calciumphosphate, incomplete precipitation, and losses of calcium oxalate during 
washing145.  
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 Liquid-liquid extraction and solid-phase extraction 
 
Extraction procedures are typically used as part of a sample preparation procedure to reduce 
the complexity of a biological sample prior to further analysis.  
Liquid-liquid extraction is a sample cleanup process that is based on separation of 
compounds according to their relative solubility in two immiscible liquids, usually water 
and an organic solvent. In the earlier methods for oxalic acid analysis especially in urine, 
liquid-liquid extraction was widely used. The fact that oxalic acid is very water soluble 
makes it difficult to extract into organic solvents, and thus very long extraction times or 
repeated extraction had to be done to obtain acceptable recoveries.  
 
Solid phase extraction (SPE) is a sample cleanup process that is used to remove compounds 
from a mixture by using the chemical and physical properties of the analyte. 
SPE is typically used to purify and concentrate the analyte before further analysis. The 
principle of SPE is liquid chromatography (see later); it is based on the affinity of the 
analyte dissolved in a liquid (mobile phase) for a solid (stationary phase) through which the 
sample is passed.  
A variety of stationary phases are available for SPE. Most of them are based on silica 
bonded to a specific functional group such as quarternary ammonium groups for anion 
exchange SPE and hydrocarbon chains of variable length like octadecyl or octyl carbon 
chain (C18 and C8, respectively) for reversed phase SPE.  
Depending on the choice of SPE conditions, either the analyte of interest or the undesired 
impurities can be retained on the SPE material. For oxalic acid, the use of anion exchange 
SPE is an example of setup where the analyte is retained on the stationary phase, while the 
use of a C18 resin will allow the oxalic acid to pass through the material unretained while 
neutral and hydrophobic components in the sample are retained.  
If the analyte is retained on the stationary phase, a washing step is typically subsequently 
performed to remove unretained and weakly retained compounds. Finally an elution step is 
performed in which a solution that disrupts the interaction between the analyte and 
stationary phase is used to elute the analyte in a small volume.  
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8.3. Analytical methods for determination of oxalic acid 
 
In the following an overview, including discussion on main advantages and disadvantages, 
of the majority of methods that has been developed for oxalic acid determination up until 
today is given.  
 
8.3.1. Chemical techniques 
 
Oxalic acid has been measured directly by quantification of it s oxidation products, or after 
initial reduction to glyoxylic acid or glycolic acid, and this was the basis of many of the 
early methods described. 
 
Oxidation in combination with titrimetry or manometry 
 
Oxalic acid can be oxidised by acidified potassium permanganate: 
5H2C2O4 + 2KMnO4 + 3H2SO4 = K2SO4 + 2MnSO4 + 8H20 + 10CO2 
 
This reaction has been the basis for many of the early methods for oxalate determination 
after initial precipitation of oxalate as calcium oxalate. As an alternative to precipitation of 
calcium oxalate, the precipitation of oxalate from serum as its cerium salt has also been 
suggested 154. However, this procedure was criticized by several authors and the existence of 
oxalate in the precipitate questioned 155.  
In the titrimetric methods, typically the persistence of the pink colour of potassium 
permanganate was used to determine the end-point of the titration. For analysis of oxalate in 
urine, an initial sample cleanup by liquid-liquid extraction of the acid into boiling peroxide-
free ether before precipitation of calcium oxalate was suggested to remove interfering 
compounds in the sample. Satisfactory recovery was obtained only after 18 hours of 
extraction 156.  
For serum, manometric determination of the CO2 evolved in the permanganate reaction has 
also been used to quantify oxalate. After an initial acidic precipitation and removal of 
plasma proteins, calcium oxalate was precipitated, supernate removed and precipitate 
redissolved with sulphuric acid before addition of permanganate and manometric 
determination of the CO2 produced157. An alternative sample preparation procedure for the 
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oxidation-manometry method was later described in which oxalate was quantitatively 
extracted from serum by esterification and distillation 158.   
In general, the methods based on precipitation of oxalate followed by oxidation by 
permanganate were very time consuming and great care had to be taken to standardize the 
temperature of the reaction. The fact that permanganate reacts with many other reducing 
substances especially in urine resulted in a general underestimation of oxalate concentration 
in methods based on the permanganate reaction. 
 
Reduction in combination with fluorimetry or colorimetry 
 
Oxalic acid can be reduced to glyoxylic acid in the presence of zinc and hydrochloric acid:     
  HO-CO-CO-OH + H2 = H-CO-CO-OH + H2O 
A fluorimetric method that initially was developed for quantification of glyoxylic acid159, 
was adapted for determination of oxalate in serum and urine. Proteins from serum or urine 
were removed by acid/heat precipitation. Before calcium oxalate precipitation, the samples 
were processed by liquid-liquid extraction with tri-n-butyl phosphate as this solvent was 
found to have a much higher partition coefficient for oxalate than e.g. diethyl ether. Oxalic 
acid was then reduced in the presence of zink and hydrochloric acid. The resulting glyoxylic 
acid was allowed to react with resorcinol, forming a fluorescent glyoxylic acid-resorcinol 
complex that had maximum emission at 530 nm160.        
The conditions used for the reduction of oxalate to glyoxylate was critical as the reaction 
was difficult to control at the glyoxylate stage, and most workers therefore preferred to 
utilize the reduction of oxalic acid into glycolic acid : 
HO-CO-CO-OH + 2H2 = HO-CH2-CO-OH + H2O 
The glycolic acid produced could readily be detected with colorimetry. By heating glycolic 
acid with concentrated sulphuric acid and chromotropic acid, the formaldehyde formed from 
breakdown of glycolic acid formed a purple complex with chromotropic acid and this 
complex was detected at 570 nm. In 1961 Hodgkinson and Zarembski described a method 
for determination of oxalate in urine using this principle. Continuous extraction of acidified 
urine with peroxide-free boiling ether for 6 hours was performed. The extracted oxalic acid 
was then precipitated as the calcium salt, reduced to glycolic acid by boiling with zinc and 
sulphuric acid and determined colorimetrically after addition of chromotropic acid156. 
However, the initial heating of acidified urine was thought to cause positive interference by 
converting oxaluric acid present in urine to oxalic acid.  Ten years later an improved method 
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for oxalate in urine was published by the same research group, based on two previous 
procedures (156 and 160).  Solvent extraction was omitted and the oxalic acid was co-
precipitated directly from urine with calcium sulphate and ethanol. The precipitated oxalic 
acid was then converted to glycolic acid and determined colorimetrically as before 161. 
Glucose in the concentration found in diabetic urine was found to cause significant 
interference. The same did glycolic acid present in concentrations found in primary 
hyperoxaluria.  
Using this method, normal men were found to excrete from 17-43 mg oxalic acid per day. 
The reduction/colorimetric procedure have also been used for determination of oxalic acid 
in plasma. Instead of liquid-liquid extraction, solid phase extraction using an ion-exchange 
resin was used for removal of interfering substances from plasma 162.  In general, the 
chemical methods involved time consuming sample preparation based on precipitation or 
continuous liquid-liquid extraction and also the use of strong acids. Since the end of the 
70’ties the chemical methods for determination of oxalic acid was largely replaced by 
enzymatic methods and also by methods based on chromatography and mass spectrometry. 
 
8.3.2. Isotope dilution techniques 
 
Isotope dilution techniques are analytical techniques that involve the addition to a sample of 
an isotopically labeled compound, either stable or radioactive. Long before isotopes were 
discovered, zoologists started using catch and release methods for estimation of fish 
populations in ponds. The principle behind this was very simple: a certain number of fish 
was caught, labeled, and released back into the pond. After the released fish was 
intermingled with all other fish in the pond, a second catch was performed and the ratio of 
labeled and unlabeled fish recorded. Since the total number of labeled fish was known, this 
ratio allowed estimation of the total fish population in the pond 163.  As an example, with 
five labeled fishes and a ratio of labeled to unlabeled fish in the second catch being 1: 4, an 
estimated 25 fish was in the pond. In isotope dilution, a known amount of labeled fish would 
be added to the pond and then the ratio of labeled-to-unlabeled measured from a 
representative sample, and this demonstrates the working principle of isotope dilution. 
For determination of oxalic acid, both isotope dilution with the radioactive isotope 14C and 
the stable isotope 13C has been used. In early methods for determination of oxalic acid in 
urine by isotope dilution, 14C2 oxalic acid was added to urine followed by overnight 
precipitation as calcium oxalate. The precipitate was washed, dried, and dissolved in 
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sulfuric acid with added zinc for reduction of oxalic acid to glycolic acid. After separating 
glycolic acid from other compounds on an ion-exchange column, aliquots were taken for 14C 
counting in a scintillation counter, and for colorimetric determination of glycolic acid164. 
The content of oxalic acid in urine was then calculated from the specific activity of the 
isolated glycolic acid (derived from oxalic acid) and the total counts of 14C2 oxalic acid 
added to the specimen ( total counts of 14C2 oxalic acid – specific activity of derived 14C 
glycolic acid = oxalate content of the specimen). Using this technique, the daily urinary 
excretion of oxalate pr 1.73 m2 of body surface in healthy children averaged 32.9mg, in 
children with PH 149-375 mg was found, and in healthy adults 18-47 mg.  
The concentration of oxalic acid in plasma is considerably lower than in urine, and in 
general far more methods have been described for oxalate urine analysis compared to 
plasma. At the same time methods for direct determination of oxalate in urine was readily 
available, but direct determination of oxalic acid in plasma was difficult and this led to the 
development of methods for indirect estimation of oxalic acid in plasma by use of isotope 
dilution. In this indirect method, radioactive oxalate, 14C2 oxalic acid, was administrated to 
the patient himself. Afterwards blood and urine samples were collected. In plasma, only 
radioactivity was measured, while in urine both radioactivity and oxalate concentration was 
measured by e.g. colorimetry 165. The concentration of oxalic acid in plasma was then 
estimated as: (14C2 oxalic acid activity pr unit volume of plasma) x (concentration of oxalic 
acid in urine)/ (14C2 oxalic acid activity pr unit volume of urine). 
Normal plasma concentrations in the range 0.5 – 1.9 mol/L was typically found using this 
technique 166, and 9-19 mol/L in PH patients166. The plasma concentrations estimated using 
14C2 oxalic acid isotope dilution was and still is of the lowest reported using any technique.   
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8.3.3. Enzymatic techniques 
 
Enzymes have the advantage of specificity when used as analytical tools in the laboratory. 
Two enzymes have been used for quantitation of oxalate; oxalate oxidase and oxalate 
decarboxylase.   
Oxalate decarboxylase 
 
Oxalate decarboxylase (EC 4.1.1.2) catalyzes the reaction: 
 
HO-C  C-OH
O  O oxalate
decarboxylase
CO2 + H-C-OH
O 
 
 
Oxalate decarboxylase can be purified from the wood-rot fungus Collybia velutipes and both 
products of the enzymatic reaction have been used for quantitation of oxalate as outlined in 
Figure 5. 
 
HO-C  C-OH
O  O oxalate
decarboxylase
CO2 + H-C-OH
O
pH change
in alkaline buffer
radioactivity
of added 14C oxalic acid
manometry
formate dehydrogenase
NAD+
oxireductase/
luciferase
luminometry
 
 
 
 
 
 
 
 
 
 
Figure 5. Different approaches for determination of oxalic acid by use of oxalate 
decarboxylase. 
 
Initially oxalate decarboxylase was used for quantitation of oxalate in plasma, and the CO2 
produced was measured by Warburg manomentry 167. A few years later the same 
manometric procedure was used for urine analysis after initial precipitation of oxalate as 
calcium oxalate that was redissolved in potassium citrate buffer 168. Phosphate and sulphate 
which are normal constituents of urine are inhibitors of oxalate decarboxylase, but by using 
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a higher concentration of the enzyme this limitation could be overcome thus making initial 
sample preparation unnecessary. The CO2 produced was released into an alkaline buffer and 
the pH change measured169. A modified version of this method was also adapted for 
plasma170. A radioenzymatic assay using oxalate decarboxylase has also been described for 
plasma oxalate. 14C labelled oxalate was added to plasma and the sample was ultrafiltered, 
calcium oxalate was then precipitated and redissolved followed by liquid-liquid extraction 
using diethylether, evaporation and redissolving in a citrate buffer. Oxalate decarboxylase 
was then added and the progress of the enzymatic reaction followed by measuring the 14CO2 
evolved in a 14C labelled oxalate standard with and without the addition of the extract from 
plasma containing unlabelled oxalate171. The radioenzymatic assay was further optimized by 
performing a direct rapid precipitation of calcium oxalate172. For urine analysis, the 
preparation of an enzyme electrode with oxalate decarboxylase entrapped in polyacrylamide 
gel retained over a CO2 sensor has been reported 173.  
Quantitative methods for oxalate based on measurement of the formate produced by oxalate 
decarboxylase have also been described. The formate produced can be measured 
spectrophotometrically by using nicotinamide adenine dinucleotide (NAD+)-requiring 
formate dehydrogenase, and this double enzyme system has been used for both serum and 
urine analysis174;175.   For plasma analysis, even a triple enzyme system has been described 
in which the NADH produced by formate dehydrogenase is determined by a bacterial 
oxidoreductase/luciferase system emmiting light that can be quantified in a luminometer 176. 
Plasma was treated with a cation exchange resin to adjust pH and remove cations before 
analysis. An immobilized version of the triple enzyme system has also been described177. 
 
 
 
 
Oxalate oxidase 
 
Oxalate oxidase (EC 1.2.3.4) catalyzes the reaction: 
 
HO-C  C-OH
O  O oxalate
oxidase
2 CO2+ H2O2
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The enzyme can be purified from many different sources such as barley roots, several 
species of moss, and from grain sorghum leaves. As shown in Figure 6, analytical methods 
have been developed based on the quantitation of both of the products formed.  
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Figure 6. Different approaches for determination of oxalic acid by use of oxalate oxidase. 
 
As for oxalate decarboxylase, the change in pH of a weak alkaline buffer arising from 
trapping of the CO2 evolved has been used for quantitation of oxalate, but the oxalate 
oxidase reaction has the advantage of producing two moles of CO2 for each mole of oxalate. 
After deproteinizing by addition of hydrochloric acid and heating, plasma oxalate has been 
quantified by this technique178. 
A number of methods have been described based on measurement of the H2O2 produced by 
the oxalate oxidase reaction. The use of a second enzyme, horseradish peroxidase that 
converts H2O2 to O2 and H2O has been the basis of several methods for oxalate 
measurement. By mixing the peroxidase with chromogens the O2 released causes oxidative 
coupling of the chromogens resulting in the formation of a coloured complex that can be 
measured spectrophotometrically at 520 or 590 nm:  
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Oxalate oxidase is inhibited by both divalent metals and several sodium salts including 
chloride, phosphate and citrate and thus different sample preparation procedures has been 
described to overcome this limitation. In addition to the potential conversion of ascorbate to 
oxalate during assay and storage, ascorbate interferes directly with the peroxidase step and 
needs to be removed prior to analysis. The divalent cations can be removed by an ion 
exchange resin and ascorbic acid can be eliminated by charcoal treatment, addition of 
sodium nitrite that converts ascorbate to dehydroascorbate or the use of ascorbate oxidase.  
For urine analysis of oxalate, a spectrophotometric method using the oxalate 
oxidase/peroxidase/coloured dye system in combination with an ion exchange and a 
charcoal cleanup step was described in 1980179. A few years later an immobilized version of 
this system that allowed reuse was reported. The sample preparation procedure included the 
initial precipitation of oxalate as calcium oxalate as the authors claimed that alternative 
methods for removal of interfering components like charcoal and ion exchange were not 
sufficient180.  A similar immobilized enzyme system was later developed for plasma 
analysis in which plasma was first ultrafiltered, acidified and then had sodium nitrite added 
for ascorbate  
elimination 181. A method suitable for the spectrophotometric determination of oxalate in 
different biological matrices using the oxidase/peroxidase/coloured dye system was then 
described in1988. Both plasma and urine could be analyzed, however the sample treatment 
used was very different including ultrafiltration and precipitation of calcium oxalate for 
plasma analysis and dilution and pre-treatment with a reversed phase cartridge for urine. 
The authors found that the use of sodium nitrite interfered with the colour development and 
the use of this reagent for ascorbate removal was therefore omitted 182. An immobilized 
version of this method was later described in which the enzyme was placed in an enzyme 
coil as part of a continuous flow system. For both urine and ultrafiltered plasma, sodium 
nitrite was added just before assay 183. 
For urine analysis a kit was introduced in 1989 employing an initial alkalization and 
addition of ethylenediaminetetraacetic acid(EDTA) (avoiding precipitation of calcium 
oxalate) in combination with charcoal treatment184.  The kit reagents were later used for 
plasma analysis. Plasma was ultrafiltered into acid to avoid oxalogenesis and was further 
treated with ascorbate oxidase for elimination of ascorbate that otherwise caused negative 
interference probably due to H2O2 being reduced by ascorbate 185.  
For plasma analysis the removal of proteins by use of sulfosalicylic acid has also been used 
followed by charcoal treatment of the supernate before assay 186. The use of oxalate oxidase 
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purified from sorghum leaves has also been reported. The main benefit of using this source 
of the enzyme was its insensitivity to chloride present in the sample. Plasma could be 
analyzed after ultrafiltering into acid and addition of sodium nitrite 187. Analytical systems 
based on the immobilization of both oxalate oxidase and peroxidase on glass beads that 
could be reused has been described for plasma analysis 188. By affixing the glass beads on a 
plastic strip the method was further improved 189.  
In addition to the number of methods based on the peroxidase-mediated colorimetric 
procedure, the use of amperometric detection of the H2O2 produced has been reported by 
several investigators. In-line systems with immobilized enzyme (immobilized enzyme 
reactors, IMER) combined with amperometric detection was introduced for plasma and 
urine analysis in the 1990’ties. Both ion-pair chromatography and anion-exchange 
chromatography, respectively, have been combined in-line with the IMER/amperometric 
H2O2 detection 190;191. For the ion-pair chromatography procedure both plasma and urine 
was purified using a C18-cartridge after plasma was deproteinized by acid and heat 190. For 
the anion-exchange chromatography procedure the C18 cleanup was not necessary, and 
plasma was analyzed only after ultrafiltering into acid 191;192 and for urine thymol and 
isopropanol was added for preservation191. “Amperometric biosensors” for urine analysis 
has also been described in which the oxalate oxidase has been immobilized onto an 
electrode. Samples had to be diluted many times to overcome the need for removing 
reductive agents present in urine. The H2O2 produced reacted with hexacyanoferrate (II) in 
the buffer solution of a flow-injection system to yield hexacyanoferrate (III) that was 
reduced back to hexacyanoferrate (II) at an gold electrode193, or the oxalate oxidase was 
immobilized on the surface of a chromium hexacyanoferrate-modified graphite electrode194. 
SIRE technology (sensors based on injection of the recognition element) has also been used 
for urine analysis of oxalate, but the technique was not sensitive enough for plasma analysis. 
In the SIRE biosensor, the oxalate oxidase was injected into a reaction chamber containing 
an integrated electrode. A small amount of enzyme was thus used for one measurement and 
then discarded which greatly increased the lifetime of the biosensor 195.  
In summary, out of the many methods published on the use of oxalate oxidase and oxalate 
decarboxylase, only a few has proven useful for analysis of both plasma and urine. The 
reported methods are in general labour intensive and special precautions must be made to 
avoid interference by endogenous substances present in biological samples. The integrated 
methods with in-line reactors or electrodes involve either the use of special custom made 
devises and/or the use of enzyme that has been purified in the lab from harvested plants.   
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8.3.4 Chromatographic techniques 
 
Chromatography is a collective term for a set of techniques used for separation of mixtures. 
A mixture dissolved in a mobile phase is passed through a stationary phase, and different 
degree of interaction between the different compounds in the sample and the stationary 
phase leads to separation of the compounds. In liquid chromatography the mobile phase is a 
liquid, and in gas chromatography the mobile phase is a gas.    
Both liquid chromatography and gas chromatography in combination with several different 
detection principles has been developed for determination of oxalic acid in biological fluids. 
 
Gas chromatography 
 
Oxalic acid itself is not suitable for gas chromatography (GC) and therefore needs to be 
chemically modified (derivatized) into a less polar, thermally stable and more volatile 
compound as part of the sample preparation procedure. 
Several methods for oxalic acid determination combining GC and flame ionization detection 
(FID) were described in the 1970’ties. For GC-FID of oxalic acid in urine, a solid phase 
extraction procedure with an anion –exchange resin was described for sample clean up. A 
recovery of  95% of oxalic acid from the anion-extraction resin was found using a 
radioactive tracer. After elution from the resin, preparation of o-ethyl oxime derivates (to 
stabilize the sample) was performed before freeze drying over night. The acids in the dried 
sample were then derivatized into trimethylsilyl esters that was separated and detected by 
GC-FID196. A similar procedure was adapted for plasma analysis, but the acids were 
derivatized into dimethyl esters before GC-FID analysis196.  
For urine, a GC-FID method without the initial extraction was also described in which 
30mL of urine was evaporated to dryness under reduced pressure with a rotating vacuum 
evaporator followed by ethylation by ethanol/sulphuric acid and GC-FID analysis197. A 
combined method for plasma and urine was also published involving initial evaporation to 
dryness, liquid-liquid extraction with ether and overnight derivatization with isopropanol 
and hydrochloric acid followed by GC-FID. The normal concentration found in plasma was 
8.9-41 mol/L and in urine 100-488 mol/24 h (detection limit 7.5 and 20 mol/L in plasma 
and urine, respectively)198. A modified version of this urine and plasma method using 
capillary GC column and without the initial evaporation to dryness was also published. 
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Ethyl acetate was used for direct repeated liquid-liquid extraction of oxalic acid from 
acidified urine or plasma. Plasma proteins were found to precipitate in the conditions used 
during extraction and repeated extraction with the precipitate in place was needed to obtain 
reliable results. In healthy volunteers, a mean urinary oxalic acid extraction of 230 mol/24 
h was found and plasma concentration in the range 1.3-5.3 mol/L150. GC in combination 
with electron capture detection has also been used for determination of a chlorinated 
derivative of oxalic acid in urine after precipitation of calcium oxalate199. 
In most of the GC methods mentioned so far, endogenous compounds present at low 
concentrations in body fluids, such as malonic acid, was used as internal standards for 
quantification of oxalic acid. Difference in extraction efficiency and reactivity towards 
derivatization reagents was an obvious drawback of this approach. The use of GC in 
combination with mass spectrometry allowed the use of isotopically labeled internal 
standard that greatly increased the selectivity (See gas chromatography-mass spectrometry 
below).   
 
Liquid chromatography 
 
In all liquid chromatography (LC) methods the mobile phase is a liquid, but a number of 
different stationary phases can be used. LC-techniques can be classified according to the 
polarity of the stationary and mobile phase. In reverse phase chromatography the mobile 
phase is more polar than the stationary phase, and opposite in normal phase chromatography 
where the stationary phase is more polar than the mobile phase. 
For reversed phase chromatography, stationary phases with hydrocarbon chains of different 
lengths like C18 or C8 are typically used. The mobile phase contains a mixture of water or 
aqueous buffers and organic solvents that are miscible with water, like methanol or 
acetonitrile.  
Relatively few reports on the use of reversed phase chromatography for oxalic acid are 
published. The retention of the highly polar oxalic acid is low on a reverse phase system, but 
in some reported methods for oxalic acid this was overcome by adding quarternary 
ammonium ions to the mobile phase as counter ions, hence increasing the retention of oxalic 
acid200. This reversed phase ion-pair LC system with a low pH mobile phase in combination 
with ultraviolet (UV) detection at 210-220 nm has been used for oxalic acid measurement in 
urine. Interfering substances had to be removed either using a C18-cartridge201 or by protein 
precipitation202 before analysis on a C8 or C18 column, respectively. The urinary oxalic acid 
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excretion found in healthy controls was in the range 100 – 225 mol/24h 202. Although 
suitable for urine analysis, poor detection limit (15 mol/L) did not allow determination of 
oxalic acid in plasma. Methods based on derivatization of urinary oxalic acid into better 
retained, more UV-absorbing compounds have also been proposed. By reacting acidified 
urine with o-phenylenediamine, a highly UV-absorbing oxalic acid derivative was formed 
that could be detected at 314 nm after chromatography on a C8 column. However, a large 
background signal was present of unknown origin and thus two separate determinations of 
each sample had to be performed; one after the urine hade been treated with oxalate oxidase 
(to remove oxalic acid from the sample) and one without enzyme treatment. The difference 
in peak area between the two determinations was used for calculation of oxalic acid 
concentration in urine 203. A different derivatization approach was also reported using 
liquid-liquid extraction of urine by tri-n-butyl phosphate followed by derivatization with 9-
anthryldiazomethane and C18 chromatography. The resulting fluorescent compound was 
measured at 410nm with excitation at 254 nm. The derivatized oxalic acid decomposed 
upon standing and the analysis therefore had to be done within 10h after preparation. 204.    
Ion-exchange chromatography, in which the stationary phase is charged, is used for 
separation of polar or charged molecules. The stationary phase surface displays ionic 
functional groups that interact with analyte ions of opposite charge leading to retaining of 
the analyte. Mobile phases typically consists of species that are similarly charged as the 
analyte and that will displace the analyte ions from the stationary phase.    
In combination with conductivity detection, this LC-technique has been the basis for several 
methods developed for determination of oxalic acid.  
In general, the chromatographic column was packed with anion-exchange material and the 
mobile phase typically consisted of a carbonate/bicarbonate buffer with boric acid. Initially 
this technique was used for oxalic acid in urine, after only dilution with water and 
filtering205. Sulphate present in urine eluted close to oxalic acid and sulphate therefore had 
to be added to the aqueous standards used for preparation of the calibration curve in order to 
overcome the potential problem of peak overlap. For plasma analysis, sample preparation 
typically involved ultrafiltering to remove proteins that otherwise results in clogging of the 
chromatographic column. However, it was shown that the time of acidification (before or 
after ultrafiltering) and the molecular weight cut-off of the ultrafilter used were of 
significant importance. Sample loss close to 50 % was observed when ultrafiltering was 
performed with a 30.000 dalton cut -off filter on plasma acidified to pH 3 due to binding of 
oxalic acid to plasma proteins at this pH. At physiological pH or at extremely low pH, 
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protein binding was not seen. At the same time oxalogenesis was observed during 
ultrafiltering if plasma was not first acidified, and initial strong acidification was therefore 
adapted to obtain satisfactory results206.  
The very pH dependent recovery and the need to acidify to avoid oxalogenesis was a 
drawback of the method. However, others claimed that plasma did not have to be acidified 
prior to ultrafiltering, and alternative sample preparation was then proposed in which 
unacidified plasma was ultrafiltered into acid207, or into a cation-exchange resin for 
reduction of pH to about 1208. Chloride present in urine could cause interference in the 
chromatogram and was removed by passing the acidified plasma ultrafiltrate through a 
silver cation-exchange resin before chromatography. The method was also used for urine, 
after passing the sample through a C18 cartridge for clean up. In healthy controls, urine 
excretion in the range 107-560 mol/day was found and plasma levels in the range 0.8 – 3.2  
mol/L208. A simpler sample preparation procedure for plasma oxalate was also described in 
which proteins were removed from plasma by precipitation with acetonitrile209. For work up 
of unacidified plasma the use of a 10 000 dalton cut-off filter has also been suggested as it 
reflects the sieve micro architecture of renal glomeruli. Using this procedure, observations 
suggesting binding of oxalic acid to plasma proteins with a molecular weight higher than the 
cut off limit was suggested210, but this was later reported to be apparent and not real by the 
same researchers211.  
Regardless of the choice of sample purification, a major concern using the ion-
chromatographic – conductivity detection methods for oxalic acid is oxalogenesis occurring 
during chromatography, in the column, from ascorbic acid present in the sample. Ascorbic 
acid therefore has to be removed before chromatography by e.g. enzymatic oxidation or 
addition of boric acid to the mobile phase 206.  
 
Although controversy exists on both the impact of in-column oxalogenesis, strategies to 
prevent it, and choice of sample pretreatment procedure, ion chromatography with 
conductivity detection is one of the most used analytical systems for determination of oxalic 
acid in use today. 
As an alternative to a charged stationary phase used in ion-exchange chromatography, a 
custom made solvent-generated ion-exchange chromatographic system with amperometric 
detection at a copper electrode has been described for measurement of oxalic acid in 
urine212.   
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Capillary electrophoresis 
 
In addition to the number of LC-methods, a CE method using indirect UV-detection has also 
been reported for analysis of oxalic acid in urine 213. Although simple and robust, the 
relative poor sensitivity of CE limited its use to urine analysis.  
 
8.3.5 Mass spectrometry 
 
The principle of mass spectrometry (MS) consists of ionizing a chemical compound in gas 
phase to generate charged molecules or molecule fragments and subsequent measurement of 
their mass-to-charge ratio (m/z).  A number of different ionization techniques are available 
like electron impact ionization typically used with GC, or the softer, electrospray ionization 
(ESI), typically used with LC.  
 The power of MS lies in the fact that the mass spectra of many compounds are sufficiently 
specific to allow their identification with a high degree of confidence. If the analyte is part 
of a complex mixture such as urine or plasma, however, all compounds present in the 
sample will produce ions and the mass spectrum obtained will be complex. If in addition the 
analyte is a minor component of the sample, identification with an acceptable degree of 
certainty is difficult.   
The combination of the capability of chromatography to separate compounds in a mixture 
allowing pure compounds to be introduced into the MS, with the identification capability of 
MS is clearly advantageous.     
After the initial use of isotope dilution with the radioactive isotope, a number of methods 
based on the use of the stable isotope of oxalic acid, 13C2 oxalic acid (1,2-13C2 oxalic acid) 
was described. Typically, 13C2 oxalic acid was added to the sample to work as an internal 
standard as the labeled analog behaved like the natural compound throughout the analytical 
procedure hereby correcting for any sample loss. The difference in molecular mass between 
the 12C  and 13C -oxalic acid  makes them easy to detect individually in mass spectrometry.  
The internal standard, 1,2-13C2oxalic acid, has a molecular weigh 2 atomic mass units (u) 
higher than the natural compound (92.03 and 90.03 g/mol, respectively).  
Interfaces for connection of GC with MS was commercially available much before 
interfaces for connection of LC and MS, and commercially available ESI interfaces has only 
been available during the last 20 years 214. The reason for the much earlier routine use of 
GC-MS is the compatibilities of the two techniques. 
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Compounds analyzed with GC have to be both volatile at the temperatures needed to 
achieve separation, and thermally stable. These are by far the same requirements needed to 
produce mass spectra from an analyte in the MS. Thus, the vast majority of compounds 
amendable to GC separation can efficiently be transferred to the MS. 
This is not the case when LC is interfaced with MS, due to the incompatibilities of the two 
techniques. Thus, an interface must be used with its prime purpose being the removal of the 
mobile phase.  
After the analyte has been ionized, the ions of different m/z ratios produced are separated 
and detected.  Several different mass separation devices are used in MS. A triple quadrupole 
mass analyzer is commonly used in combination with LC and ESI.   
   
 
 
Gas chromatography-mass spectrometry 
 
Several methods based on gas chromatography-mass spectrometry (GC-MS) using 13C2 
oxalic acid have been described. In a GC-MS method for urine analysis published in 1979, 
the 13C2 oxalic acid internal standard was added followed by ethanol and CaSO4. After 
overnight precipitation and drying of calcium oxalate, derivatization reagent was added to 
the residue followed by heating. The resulting di-propyl ester of oxalic acid was then 
extracted into hexane and injected on the GC-MS. Oxalic acid eluted after less than 3 
minutes from the GC and the protonated molecule formed in the MS after chemical 
ionization was at m/z 175.0 (endogenous oxalic acid) and 177.0 (13C2 oxalic acid). 
Using selective ion monitoring, the ratio of the m/z 177.0 and 175.0 was used to quantify 
oxalic acid in the urine sample215. Several similar methods but with different derivatization 
procedures was later reported for urine analysis, e.g. with the formation of the di-isopropyl 
ester of oxalic acid that could be quantified at m/z 194 and 192 (ammonium-adduct of the 
molecule) for the internal standard and endogenous compound, respectively216. As an 
alternative to the precipitation of calcium oxalate, liquid-liquid extraction of urine with ethyl 
acetate has been reported followed by lyophilizing and an overnight derivatization 
procedure resulting in the formation of bis-(tert.-butyl-dimethylsilyl) derivates of oxalic acid 
that could be quantified by GC-MS with electron-impact ionization. The latter method was 
developed to monitor intestinal absorption of oxalic acid by administrating 13C2 oxalic acid 
and isotopically labeled malonic acid was actually used as internal standard for both labeled 
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and unlabeled oxalic acid. The use of ethyl acetate for extraction was not very efficient, and 
only about 50% of the oxalic acid was retained in the ethyl acetate phase after washing. A 
mean excretion of 0.335 mmol oxalic acid/24h was found in healthy female volunteers, and 
absorption of ingested 13C2 oxalic acid in the range 1-48% 217. Stable isotope-dilution GC-
MS determination of oxalic acid in plasma has also been described. After initial addition of 
the isotopically labeled internal standard, plasma was acidified followed by solvent 
extraction with ethyl acetate and derivatized into trimethylsilyl-derivates that was quantified 
in the MS218.  
 
 
 
 
 
 
Tandem mass spectrometry 
 
Tandem mass spectrometry (MSMS) is a term that covers techniques in which one stage of 
MS is used to isolate an ion of interest and second stage of MS is then used to probe the 
relationship between this ion with others from which it have been generated or generate on 
decomposition.   
The triple quadrupole is probably the most widely used MSMS-instrument. As the name 
suggests, the hardware consists of three sets of quadrupole rods in series.  The second set of 
rods is not used as a mass separation device but as a collision cell where fragmentation of 
ions transmitted by the first set of quadrupole is carried out.  
The most used MSMS experiments in LC-MSMS are product ion scan, precursor ion scan, 
constant neutral loss scan, and selected decomposition monitoring or multiple reaction 
monitoring (MRM).  
In MRM, the fragmentation of a selected precursor ion to a selected product ion is 
monitored.  
This is performed by setting the first quadrupole to let only ions of one m/z (typically the 
molecular ion) pass on to the second quadrupole. This so called precursor ions is then 
fragmented into product ions in the second quadrupole and the third quadrupole is set to 
allow only fragments of one m/z pass on to the detector. The m/z of the precursor (first 
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quadrupole) and the selected product (third quadrupole) is often referred to as the MRM-
transition. 
Figure 7 is a schematic of a triple quadrupole used in MRM mode.  
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Figure 7. Schematic of a triple quadrupole mass spectrometer in multiple reaction 
monitoring (MRM)-mode. 
 
 
 
Liquid chromatography-tandem mass spectrometry 
 
The combination of LC and MSMS is a powerful hybrid analytical method, and the growth 
in applications of this technique is exponential. For LC-MSMS analysis of compounds in 
biological samples, an isotopically labeled internal standard is typically added followed by 
some sort of sample clean up to remove proteins or reduce ionic strength. The analyte is 
then either analyzed directly or derivatized and separated from interfering compounds on a 
reversed phase column. MS-detection is often performed in MRM-mode. 
During the work on this doctoral thesis, one method for determination of oxalic acid in urine 
using LC-MSMS was published. Urine was analyzed after only dilution and addition of 13C2 
oxalic acid and injected on a reversed phase/weak anion exchange column without prior 
derivatization. The native oxalic acid and isotopically labeled internal standard was detected 
by MRM in negative ionization mode. However, the method was not sensitive enough for 
plasma determinations as the lower limit of quantitation was 100 mol/L219.   
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Objectives of the Thesis 
 
Reliable quantitation of oxalic acid in body fluids is of great importance in several medical 
conditions, both inherited and acquired. For laboratory diagnosis of the inborn errors of 
metabolism primary hyperoxaluria type I and II (PH I and PH II), elevated concentration of 
oxalic acid is the biochemical hallmark. Environmental or secondary hyperoxaluria can be 
caused by increased ingestion and/or absorption of dietary oxalic acid, intestinal disease or 
surgery or alterations in intestinal bacterial flora. Oxalic acid is eliminated from the body by 
the kidneys, and excess oxalic acid can precipitate as calcium oxalate and cause tissue 
damage. Therefore, end-stage renal failure can be expected to involve a risk of elevated 
body burden of oxalic acid, regardless of the underlying disorder. 
Despite the importance of quantitation of oxalic acid, no analytical method has been 
available with satisfactory performance characteristic for both plasma and urine analysis to 
be used in a routine clinical lab. The combination of different pre analytical and analytical 
factors has lead to an extensive variation in normal ranges of oxalic acid reported using 
different analytical procedures. For urine analysis of oxalic acid, the use of 24-h urine 
collection has traditionally been performed. Especially in children this is cumbersome and 
non-compliance is common.  
For diagnosis of PH, a normal or close to normal 24-h urinary excretion of oxalic acid may 
be observed with deteriorating kidney function. However, the oxalic acid/creatinine ratio 
remains elevated.  
      
The main aim of the thesis was to (1) develop a state of the art method for determination of 
oxalic acid for analysis of both plasma and urine and (2) estimate the normal range of the 
metabolite in a healthy population, to (3) gain knowledge of oxalic acid dynamics following 
kidney transplantation in non-PH patients and (4) to investigate the diurnal excretion patter 
of oxalic acid to assess the usefulness of relating oxalic acid to creatinine in spot urine as an 
alternative to the traditional 24 h-urine collections.   
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 Specific objectives of the projects: 
 
Paper I 
The aim of this study was to develop a reliable and user friendly method for oxalic acid 
determination in plasma and to evaluate the performance characteristics of the method. To 
be able to recognize elevated levels of oxalic acid, the normal range of the metabolite in a 
healthy population also had to be established.  Further, the impact on pre analytical factors 
on the quantitative results was investigated including delayed processing and variable 
storage conditions.   
 
Paper II 
It is well recognized that in PH patients calciumoxalate deposits in the kidneys can lead to 
organ damage and eventually ESRF. Following kidney transplantation in PH, 
resolubilization of oxalic acid from extra-renal deposits may result in recurrence of kidney 
failure and repeated kidney transplantation may therefore bee needed. Theoretically, oxalic 
acid may be harmful in all patients with ESRF regardless of the underlying disorder. 
Elevated levels of plasma oxalic acid in non-PH patients with ESRF have been reported. 
However, little has been known about the oxalic acid dynamics following kidney 
transplantation in these patients. The aim of this study was therefore (1) to find out to what 
extent plasma oxalic acid was elevated in non-PH kidney transplant recipients and the effect 
of kidney transplantation on plasma oxalic acid levels and (2) to try and identify 
determinants of plasma oxalic acid following kidney transplantation by collecting and 
analyzing data on relevant demographic and laboratory parameters.     
 
 
Paper III 
The aim of this study was to evaluate the usefulness of the plasma method for analysis of 
oxalic acid in urine. Secondly, as the collection of 24-h urine is cumbersome it was 
desirable to investigate weather 24-h urine collections could be substituted with the much 
simpler spot urine collection. The establishment of precursory reference intervals for spot-
urine oxalic acid/creatinine-ratio in both children and adult, without diet restrictions was 
investigated.   
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Methods 
 
Paper I 
LC-MSMS is a powerful analytical tool routinely used in hospital laboratories for 
quantitation of a number of metabolites in biological samples. The use of MSMS in MRM 
mode allows detection with a high degree of confidence. The use of isotopically labeled 
13C2-oxalic acid as internal standard can compensate for eventual sample loss during sample 
preparation and is easily separated from the native compound in MRM. Therefore, LC-
MSMS in MRM mode with 13C2 oxalic acid as internal standard was the natural choice as a 
starting point for method development. Some sort of sample preparation is needed to reduce 
the complexity of the sample and avoid clogging of the chromatographic column. Being a 
strong acid, oxalic acid is readily retained on a strong anion-exchange (SAX) solid phase 
extraction (SPE) material and as this sample preparation technique can easily be automated 
it was chosen as the preferred sample preparation procedure. Native oxalic acid can be 
ionized in negative ionization mode in the mass spectrometer, but the ionization efficiency 
is low and thus low sensitivity is obtained. Fortunately, oxalic acid is easily derivatized by 
heating with acid and alcohol, and the resulting di-esters are readily ionized in positive 
ionization mode in the mass spectrometer. In addition they produce fragments with high 
abundances that can be used for MRM measurements. Di-esters of different chain lengths 
were therefore prepared and tested. Compared to the native compound, the di-esters are also 
much more hydrophobic and thus a reversed phase chromatographic system was adapted for 
the LC separation. 
The method was validated in terms of assessment of limit of quantitation, linearity, within-
day repeatability, LC-MSMS repeatability and long-term reproducibility. Absolute recovery 
during the steps of sample preparation was investigated using a radioactive isotope of oxalic 
acid, 14C2-oxalic acid, and recovery relative to the internal standard was tested. 
The impact of delayed processing of plasma after intake of the main contributor to in vitro 
oxalogenesis, vitamin C, was also assessed. Finally, the impact of storage temperature on 
long term stability of samples was investigated.    
Once the analytical method was validated including establishment of pre-analytical 
procedure, the normal range of oxalic acid in plasma was established by analyzing samples 
from healthy individuals. Samples from some PH patients were also analyzed.      
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Paper II 
A total of 213 patients admitted for kidney transplantation at Oslo University hospital 
Rikshospitalet were recruited during a period of 15 months. One patient with a plasma 
oxalic acid of 157 mol/L at time of transplantation was later found to have PH1 and was 
excluded from the study. Relevant demographic data for all patients were collected. The 
mean recipient and donor age were 51 and 49 years, respectively, and 64 % of the patients 
were men. Approximately half of the patients received a transplant from a live donor. One 
third of the patients were transplanted preemptively (did not receive dialysis treatment at 
time of transplantation) and 14 % had non primary function (did receive dialysis treatment 
up to 10 weeks follow up). The median time in renal replacement therapy (dialysis 
treatment) prior to transplantation was one year. Samples for oxalic acid were collected at 
the same time as samples for standard laboratory evaluation both pre transplantation and at 
10 weeks follow up. However, to avoid oxalogenesis, the vials with plasma for oxalic acid 
determination were processed quickly after collection and stored at -70 if not assayed 
immediately. Data on plasma creatinine, calcium, phosphate, albumin, hemoglobin, and urea 
were also collected at both time points and GFR at follow up. Adequate samples for oxalic 
acid were obtained for 99 and 167 out of the 213 at transplantation and follow up, 
respectively. Univariate relationships were evaluated by means of Spearman’s correlation 
coefficients. The determinants of oxalic acid were investigated by multivariate regression 
analysis, and values for plasma oxalic acid, creatinine, urea and PTH had to be log 
transformed to be normally distributed before entering the statistical model. 
       
 
 
Paper III 
The analytical method from paper I was adaptable for urine analysis only after dilution of 
urine 1:9 with water. Within batch precision was tested, and relative and absolute recoveries 
were investigated using the same protocol as for plasma. As precipitation of calciumoxalate 
is highly pH dependant, absolute recoveries of oxalic acid at different sample pH were also 
assessed. An enzymatic kit based on oxalate oxidase is commercially available for urine 
analysis of oxalic acid. The current method was compared to the kit by analyzing the same 
urine samples with both methods and comparing the results by t-test on ratios. To 
investigate the possible use of spot urine oxalic acid/creatinine-ratio, the diurnal patterns of 
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oxalic acid and creatinine were investigated in a group of healthy individuals who collected 
every void during 24 h in separate containers. 
Finally, spot urines from children presumably healthy with respect to hyperoxaluria 
disorders and healthy adult males and females were collected and analyzed and precursory 
reference intervals for oxalic acid /creatinine-ratio estimated by linear regression.     
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Main findings 
Paper I 
Derivatization of oxalic acid into di-butyl esters of three different chain lengths were 
initially tested (propyl, butyl, and pentyl). The di-butyl ester gave the most satisfactory 
result and was used for further method development. In the MS, the di-butyl ester of oxalic 
acid and the internal standard 13C2-oxalic acid produced molecular ions corresponding to the 
protonated molecules (MH+) at m/z 203 and 205, respectively. The main fragments 
produced in the collision cell were due to the loss of one butyl group (m/z 57). The 
transition from the molecular ion to the butyl fragment was chosen as MRM transitions; 
205.1 – 57.1 and 203.1-57.1 for the internal standard and native compound, respectively. 
Satisfactory sample cleanup was obtained by SAX-SPE and elution with acidified organic 
solvent. Initially, hydrochloric acid in methanol was used, but due to the potential formation 
of methyl esters in the proceeding derivatization (if the solvent was not removed properly), 
acetonitrile was instead used. Chromatographic performance was obtained using a regular 
C-8 reverse phase column and a mobile phase of 60 % acetonitrile in water. The assay was 
found to be linear up to 200 mol/L using aqueous standards, and the limit of quantitation in 
plasma was 0.5 mol/L. For within-day repeatability, an average coefficient of variation 
(CV) of 4.5 and 6.9% was found for an aqueous standard and for plasma, respectively. Due 
to oxalogenesis, a real plasma sample could not be implemented as long-term quality 
control, and the use of artificial plasma was not compatible with the chromatographic 
system. As an alternative, an aqueous standard was implemented as quality control, and over 
a 3 moths period a CV of 5% was found. 
Relative recovery, as tested by spiking plasma with 5-200 mol/L oxalic acid, resulted in a 
satisfactory recovery of over 90% at all concentrations tested. Absolute recovery, as tested 
by addition of radioactive oxalic acid, revealed that sample loss was minimal during SPE 
and the first evaporation step. In contrast, the sample loss during the second evaporation 
step, after derivatization, was found to be substantial and only about 25% of the oxalic acid 
originally present in the sample was recovered. These experiments clearly showed that the 
dibutyl-ester was far more volatile than the native compound and that the second 
evaporation step had to be performed under very mild conditions. 
The level of oxalogenesis in fresh plasma was tested with and without vitamin C. 
Significantly higher oxalogenesis was observed both when vitamin C was ingested and 
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when it was added directly to the sample. The results revealed that samples must be 
processed without delay following collection to avoid significant oxalogenesis.  
The effect of storage time up to eight weeks on samples stored at -20 and -70°C was also 
investigated. Oxalogenesis was observed after storage at both temperatures, and the absolute 
increase measured was found to be negatively related to the initial value.   
Finally, the normal range of oxalic acid in plasma was found by analyzing plasma from 67 
apparently healthy adult men and women without any dietary restrictions. No statistically 
significantly differences in plasma oxalic acid between the genders or age dependency were 
found. The data were log-normally distributed and by regression analysis the normal range 
was found to be 3-11 mol/L, which is in the middle range of normal ranges reported in the 
literature. In three PH-patients, plasma concentrations in the range 50-170 mol/L were 
found. 
 
Paper II 
At transplantation, 98 % of the plasma oxalic acid concentrations were above the upper 
reference limit. The saturation limit for calcium oxalate in plasma has been reported to be in 
the range 35-40 mol/L meaning that at higher levels there is a risk for precipitation. 
Almost 40% of the patients had plasma levels above 40 mol/L. At 10 weeks post 
transplant, still more than one third of the patients had oxalic acid levels above the upper 
reference limit. In patients with elevated oxalic acid at follow up, a higher average 
creatinine value (144 mol/L) compared to those with oxalic acid within the normal range 
(108 mol/L) was found. The correlation analysis of the data at transplantation revealed that 
oxalic acid was statistically significantly correlated both to preemptive transplantation, 
phosphate and creatinine. However, in the subsequent multiple regression analysis only 
preemptive transplantation and creatinine retained significance. This finding supports the 
hypothesis that oxalic acid concentration increases with declining kidney function.  At 10 
week follow up, both phosphate, creatinine, urea, albumin, and hemoglobin at 10 weeks, 
recipient and donor age, rejection episodes, GFR, and baseline PTH were found to correlate 
significantly with oxalic acid. Although all these parameters were entered into the 
subsequent regression model, only donor age, creatinine and GFR were retained as 
significant determinators of oxalic acid. These results revealed that the plasma level of 
oxalic acid at transplantation was not important for the reduction in plasma oxalic acid 
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observed following transplantation, but that establishment of adequate kidney function is the 
major determinant for excretion of the excess oxalic acid. 
 
Paper III 
The method originally developed for plasma was found to work excellent for urine after 
only dilution of the sample. The within batch CV did not exceed 6.9 % at any concentration 
tested (4.5 – 105 mol/L in diluted sample). A satisfactory mean relative recovery of 97% 
was found for urine spiked with 5-200 mol/L oxalic acid. In regard to absolute recovery, 
the same pattern as for plasma was observed; minor loss of oxalic acid during SPE and the 
first evaporation step but significant loss of the derivatized oxalic acid in the second 
evaporation step emphasizing the importance of evaporation using low gas flow and 
moderate temperature. Extreme acidification of urine resulted in higher sample loss during 
SPE, but the absolute recovery for the whole analytical procedure did not show any strong 
pH dependence.  From the analysis of 21 urines evenly distributed from 21 -1025 mol/L  
by both the current method and the enzymatic kit, it was found that the current method gave 
7.9 % higher values than the enzymatic kit, independent of the oxalic acid concentration. 
Quantitation of oxalic acid and creatinine in every void during 24 hours from 9 healthy adult 
volunteers (giving a total of 57 samples) revealed no significant time dependent variation in 
oxalic acid/creatinine-ratio. These data suggested that random spot-urines could be used as 
an alternative to timed urine collection. The variation of oxalic acid, creatinine and oxalic 
acid/creatinine-ratio in 47 children (age 1 month-17years) presumably healthy with respect 
to hyperoxaluria disorders revealed that oxalic acid excretion did not differ significantly 
between boys and girls. However, the strong age dependency of creatinine excretion 
resulted in a decrease in oxalic acid/creatinine-ratio with age. In 56 healthy adults (age 24-
76 years) a slightly decreasing oxalic acid excretion with age was observed, but regression 
analysis revealed no age dependence in oxalic acid/creatinine-ratio. Men were found to have 
slightly higher oxalic acid excretion compared to women, but as a result of the significantly 
higher creatinine excretion in men, this gender had significantly lower oxalic acid/creatinine 
-ratio. Using linear regression, precursory reference intervals for children and adults were 
calculated as 95% central intervals. For children under one year age, 78-160 mol oxalic 
acid/mmol creatinine was found as the normal range, dropping to 17-34 mol oxalic 
acid/mmol creatinine at age 17 years which concurred with the values found in the adult 
population. 
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Conclusions of the Thesis 
 
A state of the art SPE-LC-MSMS method for determination of oxalic acid in plasma and 
urine has been developed, characterized and validated. The method is based on an initial 
addition of an isotopically labeled internal standard 13C2-oxalic acid followed by a sample 
cleanup step using a strong anion exchange resin. Oxalic acid is retained on the material 
while neutral and positively charged interferences are not thus reducing the complexity of 
the resulting sample obtained when the analyte is eluted off the resin with acidic 
acetonitrile. After evaporated to dryness, derivatization is performed with addition of acidic 
butanol and heating for 15 minutes. The resulting di-butyl esters are volatile and removal of 
excess derivatization reagent must be performed under mild conditions to avoid 
unacceptable sample loss. The analyte is separated from the main matrix components by 
reversed phase LC connected to a triple quadrupole MSMS, and oxalic acid and the internal 
standard quantified using MRM. Using the developed method, the normal range of oxalic 
acid in plasma following an unrestricted diet was found to be 3-11 mol/L, which is in the 
middle range of normal ranges reported in the literature. Vitamin C results in significant 
oxalogenesis in plasma if samples are left at room temperature for extended periods of time. 
After collection, samples must therefore be assayed latest within one hour or stored at -
70°C. Even in frozen samples oxalogenesis occurs, and samples should therefore be stored 
for no longer than one week before analysis to obtain reliable results. 
In patients with end-stage renal failure not due to PH and who were admitted for kidney 
transplantation, significantly elevated plasma levels of oxalic acid was found in 98% out of 
the 212 patients included in the study. More than one third of the patients had oxalic acid 
levels above the saturation limit for calciumoxalate in plasma, indicating a potential risk of 
oxalosis.  
The independent determinants of oxalic acid at transplantation were found to be plasma 
creatinine and preemptive transplantation, pointing to the important role of the kidney in 
removing oxalic acid from the body; when the kidneys ability to excrete oxalic acid drops, 
the plasma level increases.   
As expected following kidney transplantation the oxalic acid levels dropped substantially 
and to concentrations below the saturation limit. However, almost 40% of the patients still 
had oxalic acid levels above the upper normal limit 10 weeks after transplantation. The level 
of oxalic acid before transplantation turned out not to be of importance for the subsequent 
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reduction. The independent determinants of oxalic acid after kidney transplantation were 
found to be GFR, creatinine and donor age. Both plasma creatinine and GFR are measures 
of kidney function, and both creatinine and oxalate and GFR at 10 weeks follow up were 
significantly correlated. A possible explanation for the fact that both creatinine and GFR 
were retained in the subsequent regression model can be that the two parameters have 
different accuracy with respect to predict oxalate levels at different levels of the two 
parameters. 
Three of the patients had extremely elevated oxalic acid levels before transplantation. In 
one, the plasma level remained elevated after transplantation and the patient was later 
diagnosed with PH.  In the other two, plasma oxalic acid dropped to close to normal levels 
after transplantation. One had a history of gastro intestinal surgery and kidney stones 
making enteric hyperoxaluria a possible explanation of the elevated oxalic acid.  
For quantitation of oxalic acid in urine, no significant time dependency in the ratio of oxalic 
acid excretion relative to creatinine excretion was found.  This indicates that creatinine and 
oxalic acid are treated similar by the kidney and that spot urine can be used as an alternative 
to 24-h urine. However, ingestion of a meal extreme in oxalic acid or its precursors may  
theoretically lead to transient elevated oxalic acid/creatinine-ratio that do not reflect the 
patients true oxalate status. In healthy children, the oxalic acid/creatinine-ratio was the same 
for boys and girls and decreased from birth and up to age 17 years due to the increase in 
creatinine excretion with age. In adults, no age dependency was found but men excreted 
more of both oxalic acid and creatinine leading to a slightly lower oxalic acid/creatinine-
ratio in this gender.   
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Future Perspectives 
 
In addition to the elevated oxalic acid found in PH, elevated glycolic acid is found in PH1 
and L-glyceric acid in PH2. Glyceric acid is normally not detectable in plasma or urine. 
In contrast to glycolic and glyceric acid, oxalic acid is elevated in several other medical 
conditions than PH. Thus, quantitation of glycolic and glyceric acid together with oxalic 
acid may provide important information in laboratory diagnosis of PH. Glycolic acid (HO-
CO-CH2-OH  mw 76.05 g/mol) and glyceric acid (HO-CH2-CH (OH)-CO-OH, mw 106.08 
g/mol) both contains one acid group and should in theory be suitable for anion exchange 
SPE, esterification and reversed phase LC like oxalic acid. Isotopically labeled analogs are 
available that can be used for reliable quantitation by MSMS in MRM-mode.  
Thus, the developed method for oxalic acid might be suited for determination of glyceric 
and glycolic acid in both plasma and urine as well, and this possibility should be 
investigated. If successful, the next step would be to estimate the normal range of glycolic 
acid in a healthy population.  
For spot urine analysis, more samples from healthy individuals should be analyzed to 
confirm the precursory reference intervals. With more data it will also be easier to conclude 
whether the slightly different oxalic acid/creatinine-ratios in men compared to women 
observed should result in the use of gender specific reference limits.  
As the current work is based on measurement of oxalic acid without any special dietary 
restrictions, it would also be interesting to test the effect in plasma and urine of ingestion of 
meals with can be expected to cause temporary increase in oxalic acid.  
The study on plasma oxalic acid following kidney transplantation in non PH patients 
revealed that the majority of these patients have pre-transplantation oxalic acid levels that at 
least in theory induce a risk of precipitation of calciumoxalate. Available reports on the 
magnitude and role of oxalosis in renal failure are not conclusive, and relatively little is 
known about oxalosis following kidney transplantation. The saturation of plasma with 
calcium oxalate may be only one out of several factors that leads to oxalosis. By 
heterotropic cardiac transplantation in rats it has been showed that the occurrence of prior 
tissue damage could represent a crucial predisposing factor in the deposition of calcium 
oxalate crystals137. Following these observations, one can only speculate on the possible 
impact of kidney tissue damage on renal oxalosis.  
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Whether the elevated plasma oxalic acid seen in the kidney transplant patients has long term 
consequences on graft function is not known today. Perhaps there is a greater risk for 
precipitation of calcium oxalate in a transplanted kidney.   
An expanded study involving assessment of oxalic acid and other relevant laboratory and 
clinical data, in combination with biopsy studies to reveal the eventual presence of calcium 
oxalate deposits would have the potential to expand our knowledge of the role of oxalic acid 
in renal failure.         
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Abstract   
Background: Patients with primary hyperoxaluria may need repeated kidney transplants due 
to damage from oxalic acid (oxalate) deposits. However, oxalate may also be potentially 
harmful in all transplant recipients. Determinants of oxalate following transplantation have 
not been well studied. 
Methods: 212 recipients admitted for transplantation were included in the study. Blood 
samples for measurement of oxalate and other relevant laboratory parameters were collected 
at baseline and subsequently 10 weeks after transplantation. We examined the bivariate 
association between plasma oxalate at transplantation and preemptive transplantation, time 
on dialysis, recipient age, creatinine, urea, phosphate, hemoglobin, PTH, albumin and 
calcium. Oxalate 10 weeks after transplantation was tested likewise including also laboratory 
parameters at baseline, primary non-function, rejection episodes, live versus deceased donor, 
donor age, and GFR at follow-up.  
Results: Median plasma oxalate concentration at transplantation was 35.0 μmol/L ( 95% 
confidence interval(CI) = 10.4- 93.9) and 98% of the values were above normal limits (2.6-
11.0). Oxalate concentration after 10 weeks was 9.0 μmol/L (4.0- 25.5), still 37% being 
above upper normal value.  
Multiple regression analysis revealed established dialysis treatment (p= 0,002) and creatinine 
(p<0,000001) as independent positive determinants of oxalate at transplantation. Oxalate at 
10 weeks was negatively associated to 51Cr-EDTA absolute GFR (p= 0,023) and positively to 
donor age (p=0,027) and plasma creatinine at 10 weeks (p= 0,03).  
Conclusion:At transplantation plasma oxalate was on average 3 times increased and above 
the upper normal limit in 98% of patients and were still above normal in 37% after 10 weeks.
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The reduction after 10 weeks is determined by GFR and donor age. Whether increased 
plasma oxalate following kidney transplantation may have long-term consequences needs 
further study. 
 3
 Key words : dialysis, end stage renal failure, kidney transplantation, oxalate. 
 
Short summary:   
Plasma oxalate concentration and determinants of oxalate at time of kidney transplantation 
and at 10 weeks follow up were examined. Oxalate values were increased and above normal 
limits in 98% and on average 7-fold increased compared to normal. After 10 weeks still 37% 
had oxalate above the upper normal value. Multiple regression analysis revealed established 
dialysis treatment and creatinine as independent positive determinants of oxalate at 
transplantation, while oxalate at 10 weeks was found to be negatively associated to 51Cr-
EDTA GFR and positively to donor age and plasma creatinine at 10 weeks. 
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 Introduction 
Primary hyperoxaluria (PH) includes two rare, well characterized autosomal reccesive 
diseases: primary hyperoxaluria type 1 (PH1) and primary hyperoxaluria type 2 (PH2). PH1 
is caused by deficiency of the liver specific peroxisomal enzyme alanine:glyoxylate 
aminotransferase and PH2 by a deficiency of the cytosolic enzyme glyoxylate reductase/ D-
glycerate dehydrogenase1. Both enzyme deficiencies results in an excess production of oxalic 
acid (oxalate), a metabolic end product that is excreted in urine. Oxalate binds to calcium 
forming calciumoxalate that is virtually insoluble at physiological pH. In PH1, progressive 
deposition of calciumoxalate often leads to deteriorating kidney function and can result in 
end stage renal disease 2. The biochemical hallmark of PH is severe hyperoxaluria, but with 
deteriorating kidney function hyperoxalemia develops.  Kidney transplantation is not 
regarded as a successful treatment option in PH1 as in most cases the disease rapidly leads to 
oxalate deposits in the transplant and subsequent graft loss is common 2;3. Therefore a 
combined liver and kidney transplant has emerged as therapy of choice since the metabolic 
defect is then also restored 3. However, still recurrence of deposits in the kidney is a problem 
due to high accumulated oxalate stores which can result in high plasma levels of oxalate 4. 
PH2 causes similar, but usually milder symptoms. Non-hereditary elevated plasma oxalate 
due to increased enteric absorption may occur with diseases of the intestine and after bariatric 
surgery 5. This may also lead to  kidney oxalate deposition and eventually renal failure and 
may also cause graft loss after kidney transplantation 6. Another major cause of oxalate 
retention is kidney failure per se, since the main excretion pathway of oxalate is glomerular 
filtration and secretion 7. When end-stage renal patients are successfully treated with a kidney 
transplant, stored oxalate may be excreted by the graft and potentially harm the transplant as 
indicated in several biopsy studies 8-10. The retention of oxalate in non-hyperoxaluria patients 
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with end-stage renal failure has not been well studied 11. We therefore initiated a prospective 
study and measured plasma levels of oxalate at the time of kidney transplantation and early 
post-transplant to assess the magnitude of hyperoxalemia in a larger series of patients. We 
also aimed to address potential determinants of plasma oxalate.  
 
 
Subjects and Methods  
Study design 
In this single centre prospective study we measured plasma oxalate at arrival in the transplant 
center and also in a stable phase on average 10 weeks after transplantation in altogether 213 
kidney recipients. The patients were recruited from February 2004 throughout May 2005. 
Due to lack of back-up for pre-analytical laboratory handling at all times, baseline samples 
could not be obtained in all cases. Samples for oxalate measurement that were not collected 
or stored correctly were excluded from the study (see “Plasma oxalate measurements”). Out 
of 213 patients, we received adequate oxalate samples at baseline for 100 patients and for 168 
patients at 10 weeks. One patient with a plasma oxalate value of 157 μmol/L at 
transplantation was later found to have primary hyperoxaluria type 1 and was excluded from 
the study leaving 212 for observation in the present study. A test for homogeneity (ANOVA) 
was performed after subdivison into three separate groups (I = oxalate data obtained only at 
transplantation, n = 45; II = oxalate data obtained both at baseline and follow-up, n = 54; III 
= oxalate data only available at follow-up, n = 113).  The test did not reveal any significant 
differences between these groups for all relevant demographic and laboratory parameters.  To 
obtain meaningful analysis of determinants of oxalate at baseline and at follow-up we 
examined only 2 groups, those with oxalate data at transplantation (n= 99) and those with 
oxalate data at follow-up (n=167). Between these two groups, the only difference found was 
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a higher proportion of live donor and preemptive transplants in the baseline cohort than those 
tested at 10 weeks, probably due to better availability of blood samples in these elective 
patients.  
The patients generally received a triple based immunosuppressive regimen comprising CNI 
inhibitor (CsA 80%, tacrolimus 20%), MMF and prednisolone. 
The demographic data of the overall cohort is shown in Table 1.   All patients signed an 
informed consent form and the study was approved by the Regional Ethics Committee.  
Statistics 
Univariate relationships were examined by means of Spearman’s correlation coefficients. To 
ensure that continuous laboratory data were normally distributed before entering multivariate 
regression analyses (backward and forward procedures), values for plasma creatinine, urea, 
oxalic acid and PTH were log transformed. SPSS version 16 was used for statistical 
calculations. Two-tailed tests were applied, and significance level=0.05 was adapted. 
 
Plasma oxalate measurements 
The plasma oxalate measurements were done on fresh samples of heparinized plasma. To 
avoid  in vitro oxalogenesis (non-enzymatic conversion of plasma constituents into oxalate), 
resulting in falsely high plasma oxalate, efforts were made to ensure optimum pre-analytical 
conditions; after collection, the samples were centrifuged without delay and the plasma was 
assayed within one hour or stored at -70°C for no longer than one week. All samples were 
assayed in duplicate. The oxalate was measured by means of solid phase extraction followed 
by derivatization and liquid chromatography – tandem mass spectrometry (LC-MSMS) as 
recently validated and described in detail 12.  
GFR at 10 weeks was measured by plasma disappearance of 51Cr-EDTA and normalized to 
1.73m2 body surface. Hemoglobin was measured on a CELL-DYN 4000 automatic 
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haematological analyzer (Abbott Diagnostics, CA, USA). All other laboratory parameters 
were measured by standard procedures on Modular Automatic Analyzer (Roche Diagnostics, 
Basel, Switzerland). Due to the vast variability in kidney function early after transplantation 
urinary parameters were not assessed. 
 
 
Results  
Median plasma oxalate concentration at transplantation was 35.0 μmol/L (CI = 10.4- 93.9) 
with 98% of the values above the upper normal value (reference: 3.0 -11.0)12. More than one 
third of the values (39%) were higher than 40 μmol/L which is considered to represent the 
saturation limit for calcium oxalate (CaOX)13. After 10 weeks oxalate concentration was 
significantly lower, with a median of 9.0 μmol/L (CI= 4.0- 25.5). Still 37% of the values 
were above the upper normal limit. In the patients with elevated plasma oxalate at follow up, 
a mean creatinine of 144 mol/L (CI: 81-309) was found versus those with plasma oxalate 
values within normal limits who had a mean creatinine of 108 mol/L (CI: 57-187). 
Two patients had extremely high oxalate values at transplantation that fell from 156 to 10 
μmol/L after 10 weeks in one and from 124 to 16 μmol/L in the other. 
 All oxalate values are depicted in Figure 1. The laboratory and biochemical data at 
transplantation and after 10 weeks are shown in Table 2.  
 
We examined univariate relationships between plasma oxalate at transplantation and 
corresponding values for creatinine, urea, phosphate, PTH, albumin, total calcium, 
hemoglobin, preemptive transplantation, time on dialysis, and recipient age. Oxalate at 
transplantation was found to be significantly correlated to both preemptive transplantation 
phosphate, and creatinine but only preemptive transplantation and P- creatinine retained 
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significance in a subsequent multivariate regression analysis: lg [oxalate at TX] = -1.0471 + 
0.8918·log [creatinine] + 0.1136· [preemptive transplantation; no = 1; yes = 0]; P-values for 
the regression coefficients were 0.0016, < 0.0001, and 0.0021 respectively. Standardized 
results from the multivariate analysis are shown in Table 3. The relationship between plasma 
oxalate and plasma creatinine at the time of transplantation is shown in Figure 2.  Patients 
who received  preemptive transplantation and patients transplanted after start of dialysis are 
shown separately. The increase in plasma oxalate with increasing creatinine values is similar 
in the two patient groups although patients receiving dialysis had oxalate values about 6.5 
mol/L higher than the preemptive patients. 
 
Oxalate at 10 weeks was tested likewise, with all laboratory parameters at 10 weeks, but also 
including all laboratory parameters at baseline, primary non-function, rejection episodes, live 
versus deceased donor, donor age and GFR at 10 weeks. Both phosphate, creatinine, albumin, 
urea, and hemoglobin at 10 weeks, baseline PTH, recipient and donor age, rejection episodes 
and GFR were found to correlate significantly with oxalate at 10 weeks. In the subsequent 
multivariate regression analysis, only GFR, creatinine and donor age retained the significance 
as determinants of oxalate:  lg [oxalate at 10 weeks] = 0.9277 – 0.4241.·log [GFR] + 
0.002224· donor age + 0.3273·log [creatinine]; P-values = 0.12, 0.02, 0.028 and 0.032 
respectively. See also Table 3.  
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Discussion 
This is the first study of a larger cohort of patients addressing plasma oxalate in kidney 
failure patients before and after transplantation. This is also the first study to address the 
determinants of plasma oxalate in these patients. The data confirm earlier more limited 
observations of very high levels of oxalate in patients with end-stage kidney failure 11. The 
increase was sevenfold compared with healthy persons.  The independent determinants of 
oxalate in multivariate regression analysis were creatinine and established dialysis treatment, 
supporting the hypothesis of increasing values with declining kidney function.  It has 
previously been shown that oxalosis, the deposition of CaOX in tissues, can be a 
complication of chronic renal failure. CaOX crystals have been found both in kidneys and 
myocardium of these patients at autopsy 14. Supersaturation of CaOX in plasma occurs when 
plasma oxalate level raises beyond 40 mol/L 13. More than one third of our patients had 
values beyond this limit at admission for kidney transplantation despite the fact that many 
had preemptive transplantation implying some residual capacity for renal excretion of 
oxalate. It was interesting to note that at time of transplantation, two of the patients had 
oxalate concentrations in the same range as found in the patient who was later diagnosed with 
primary hyperoxaluria. In one of these patients the elevated plasma oxalate might have been 
due to enteric hyperoxaluria. Distal parts of ileum and coecum had been removed due to 
accidental thrombosis 25 years before transplantation and she developed several kidney 
stones and was transplanted with a live donor a year after start of dialysis. The other patient 
with grossly elevated plasma oxalate at transplantation had no history of gastrointestinal 
disease or GI surgery and had a clinical diagnosis of nephrosclerosis. However, at 10 weeks 
follow up, the two non-PH patients had oxalate values at, or slightly above the upper 
reference limit, while the PH patient still had oxalate values tree times the upper reference 
limit (results not shown).  
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The severity of oxalosis has also been found to be related to the duration of renal 
insufficiency 14. However, we could not demonstrate that plasma oxalate concentration at the 
time of transplantation was significantly associated with the time on renal replacement 
therapy.   Our results might have been biased in patients who had started regular dialysis 
treatment since it is well recognized that plasma oxalate is readily removed by dialysis 15, and 
is thus reduced after each treatment session and increases by refilling from extra-vascular 
stores until the next dialysis session .Therefore the time elapsed since last dialysis session 
may have influenced the results. We have limited information on the time elapsed from the 
last dialysis session to the time of blood sampling at admission for transplantation. However, 
analysis of data from preemptive patients revealed the same relationship between oxalate and 
creatinine substantiating that increasing retention of oxalate occurs with declining kidney 
function. 
Median plasma oxalate at 10 weeks was 9 mol/L indicating some 75% reduction of plasma 
oxalate compared with the values at admission for transplantation. This finding was not 
surprising but has not previously been reported in the literature. Interestingly more than one 
third of the patients still had values above the upper reference limit for healthy controls, and 
one had a value beyond the supersaturation level of 40 mol/L. This is in contrast to findings 
in a previous small study of 8 patients undergoing living related kidney transplantation 11 
where plasma oxalate was found to be in the normal range three days post transplant although 
a tendency for higher oxalate levels was observed when compared with controls. The lack of 
statistical significance might be attributed to the inter-individual variability and the fact that 
the above mentioned study only comprised eight patients. Episodes of kidney stones were not 
recorded in any patient. Episodes of urinary tract obstruction were caused by lymphocele or 
uretheral necrosis, in no case was obstuction caused by stone in the transplant urinary tract. 
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We demonstrated that kidney function at 10 weeks as measured by plasma 51EDTA GFR 
(and also plasma creatinine) and donor age were the only determinants of oxalate in 
multivariate regression analysis. Baseline level of oxalate was not a predictor for the 
reduction at 10 weeks indicating that the plasma load of oxalate at the time of transplantation 
is not important for the subsequent reduction in plasma oxalate. By contrast establishing of 
an adequate kidney function for excretion of the excess oxalate load is obviously of 
importance. However we could not find that primary non-function of the kidney transplant 
was of importance as long as an acceptable function was established within the first few 
weeks. 
The measurement of oxalate in biological fluids has been challenging, especially due to in 
vitro oxalogenesis, leading to erroneously high plasma oxalate from the autooxidation of 
ascorbate into oxalate after sampling and even during assay 16. Thus, to obtain reliable 
quantitative results, samples for oxalate determination must be processed expeditiously.  
We found that 37% of the patients studied had plasma-oxalate above the upper reference 
limit after 10 weeks. This could at least theoretically have been attributed to oxalogenesis, if 
sample collection and pretreatment had not been standardized. However, all samples included 
in this study have been handled according to protocol. The few samples that had not been 
correctly treated (e.g left at room temperature after collection etc) were excluded from the 
present analysis.  
 
 
 
Strengths of the study 
The study is prospectively performed and the analyses are well validated 12. This is the first 
study of a larger cohort of patients with kidney failure measuring plasma oxalate before and 
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after transplantation. This is also the first study of the determinants of plasma oxalate in these 
patients.       
 
Limitations 
The plasma concentrations of oxalate may not be representative of the tissue damage 
observed in biopsy and autopsy studies. The importance of the hyperoxalemia in these 
patients remains obscure and needs follow-up studies of clinical endpoints or simultaneous 
protocol biopsies addressing oxalate deposits in the kidney transplants.     
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Table 1. Demographic and transplant data for 212 kidney transplant patients 
 
Variables 
 
 
Number of patients 
  
212 
 
Recipient age 
 
51 (11-81) 
 
Sex male/female (%) 
 
135/77 (64/36) 
 
Donor age, years (range) 
 
49 (1-77) 
 
Live donor transplants  (%)  
 
118 (49) 
 
Preemptive transplantation   (%) 
 
53 (25) 
 
Dialysis time, median in months (range) 
 
12,8 (0 – 369) 
 
Non primary function  (%) 
 
29 (14) 
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Table 2. Laboratory data for 212 kidney transplant patients at transplantation and after 10 weeks. 
  
At TX 
  
After 10 weeks 
  
Ref. interval 
  
N 
 
Median 
 
95% central 
interval 
 
%  
below lower/ 
above upper  
ref. limit 
 
N 
 
Median 
 
95% central 
interval 
 
%  
below lower/  
above upper  
ref. limit 
  
P-oxalate (mol/L) 99 35 10.4 – 93.9 0/98 167 9 4.0 – 25.5 0/37  3 – 11 
 
P-creatinine (mol/L) 
>15y: 
>15y: 
 
212 
 
 
597 
619 
 
 
284 – 968 
252 – 1110 
 
 
0 / 100 
0 / 100 
 
167 
 
 
95 
122 
 
 
54 – 163 
64 – 303 
 
 
0 / 60 
0 / 72 
  
 
50 – 90 
60 – 105 
 
P-Calcium (mmol/L) 
 
212 
 
2.38 
 
2.01 – 2.78 
 
10 / 18 
 
167 
 
2.41 
 
2.05 – 2.83 
 
5 / 23 
  
2.15 – 2.51 
 
P-Phosphate (mmol/L) 
>16y: 
 16-49 y: 
50y: 
 
212 
 
 
1.7 
1.75 
1.6 
 
 
0.8 – 2.81 
0.66 – 3.1 
0.89 – 2.55 
 
 
0 / 63 
0 / 50 
0 / 60 
 
167 
 
 
0.8 
0.9 
0.8 
 
 
0.4 – 1.29 
0.6 – 1.28 
0.39 – 1.40 
 
 
60 / 0 
25 / 0 
28 / 0 
  
 
0.9 – 1.5 
0.8 – 1.7 
0.8 – 1.4 
 
P-Albumin (g/L) 
18-39y 
40-69y 
   70y: 
 
211 
 
 
42 
40.5 
40 
 
 
33.8 – 47 
31 – 47 
32 – 46 
 
 
6 / 0 
12 / 8 
11 / 6 
 
167 
 
 
42 
40 
38 
 
 
34.4 – 46.9 
32.0 – 44.0 
26.0 – 40 
 
 
2 / 0 
7 / 0 
7 / 0 
  
 
36 – 48 
36 – 45 
34 – 45 
 
P-Urea  (mmol/L) 
 18-49y: 
 50y: 
 18-49 y: 
50y: 
 
212 
 
 
22.5 
17.9 
19.2 
19.3 
 
 
9.16 – 45.6 
7.5 – 34.1 
8.72 – 36.8 
5.88 – 36.58 
 
 
0 / 100 
0 / 100 
0 / 100 
0 / 96 
 
167 
 
 
8.55 
9.35 
8.45 
11.9 
 
 
3.5 – 15.9 
3.20 – 23.10 
2.75 – 16.17 
3.83 – 31.24
 
 
0 / 61 
0 / 65 
0 / 54 
0 / 70 
  
 
2.6 – 6.4 
3.1 – 7.9 
3.2 – 8.1 
3.5 – 8.10 
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Table 3. Multivariate regression analysis of oxalate at transplantation and after 10 
weeks.  
  
At TX 
  
After 10 weeks 
 
 
 
Variables 
 
Standardized 
coefficients 
 
 
p-value 
  
Standardized 
coefficients  
 
 
p -value 
 
Preemptive 
transplantation 
 
 
0.243 
 
0.0021 
   
NS 
 
Recipient age 
 
 NS   NS  
Donor age 
 
 NA  0.167 0.028  
Rejection 
 
 NA   NS  
GFR 
 
 NA  -0.248 0.02  
P-creatinine a,b 
 
0.591 a <0.0001   0.229 b 0.03  
P-phosphate a,b 
 
 NS   NS  
P-albumin b 
 
 NS   NS  
P-urea b 
 
 NS   NS  
P-oxalate a 
 
 NS   NS  
NA= not applicable; NS,not statistically significant; a At transplantation;  b After 10 weeks  
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Legend to Figure 1. 
All plasma oxalate measurements at transplantation (n=99) and after 10 weeks (n=167).  The 
horisontal dashed line indicates the upper normal reference limit for plasma oxalate. Two 
exceptionally high values at baseline (124 and 156 mol/L) are indicated by an asterix (). 
Paired observations in the same patient are connected with lines. 
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Legend to Figure 2: 
 
Variation of plasma oxalate with plasma creatinine at the time of transplantation ( = 
patients on dialysis,  = preemptive patients). Trend lines (solid for dialysis and dotted for 
preemptive), with formulas and corresponding correlation coefficients are shown.  
Two exceptionally high oxalate values (124 and 156 mol/L) are indicated by an asterix (). 
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